                                     Europace (2023) 25, 1249–1276                                                                                   EHRA DOCUMENT
                                     https://doi.org/10.1093/europace/euac123




EHRA expert consensus document on the
management of arrhythmias in frailty




                                                                                                                                                                                                      Downloaded from https://academic.oup.com/europace/article/25/4/1249/7036349 by Uniwersytet Jagiellonsky w Krakowie user on 05 August 2024
syndrome, endorsed by the Heart Rhythm
Society (HRS), Asia Pacific Heart Rhythm
Society (APHRS), Latin America Heart Rhythm
Society (LAHRS), and Cardiac Arrhythmia
Society of Southern Africa (CASSA)
Irina Savelieva (Chair)1*, Stefano Fumagalli (Co-Chair) 2*,
Rose Anne Kenny (Co-Chair) 3, Stefan Anker4,5,6,7, Athanase Benetos 8,
Giuseppe Boriani 9, Jared Bunch10,11, Nikolaos Dagres12, Sergio Dubner 13,
Laurent Fauchier 14, Luigi Ferrucci 15, Carsten Israel16, Hooman Kamel17,
Deirdre A. Lane 18,19,20,21, Gregory Y.H. Lip18,19,20,21, Niccolò Marchionni 22,
Israel Obel23, Ken Okumura24, Brian Olshansky 25,26,27, Tatjana Potpara 28,29,
Martin K. Stiles 30, Juan Tamargo 31, and Andrea Ungar 2
Document Reviewers: Jedrzej Kosiuk (EHRA Review Coordinator)32,
Torben Bjerregaard Larsen33, Borislav Dinov32, Heidi Estner34, Rodrigue Garcia35,
Francisco Manuel Moscoso Costa36, Rachel Lampert37, Yenn-Jiang Lin38, Ashley Chin39,
Heliodoro Antonio Rodriguez40, Timo Strandberg41, and Tomasz Grodzicki42
1
 Cardiovascular Clinical Academic Group, Molecular and Clinical Sciences Research Institute, St George’s University of London, London, UK; 2Department of Experimental and Clinical Medicine,
Geriatric Intensive Care Unit and Geriatric Arrhythmia Unit, University of Florence and AOU Careggi, Florence, Italy; 3Mercer’s Institute for Successful Ageing, Department of Medical Gerontology,
St James’s Hospital, Dublin, Ireland; 4Department of Cardiology (CVK), Germany; 5Berlin-Brandenburg Center for Regenerative Therapies (BCRT), Germany; 6German Centre for Cardiovascular
Research (DZHK) partner site Berlin, Germany; 7Charité Universitätsmedizin Berlin, Germany; 8Department of Geriatric Medicine CHRU de Nancy and INSERM U1116, Université de Lorraine,
Nancy, France; 9Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy; 10(HRS representative):
Intermountain Medical Center, Cardiology Department, Salt Lake City, Utah, USA; 11Stanford University, Department of Internal Medicine, Palo Alto, CA, USA; 12Heart Center Leipzig, Department
of Electrophysiology, Leipzig, Germany; 13(LAHRS representative): Clinica Suizo Argentina, Cardiology Department, Buenos Aires Capital Federal, Argentina; 14Centre Hospitalier Universitaire
Trousseau et Université François Rabelais, Tours, France; 15National Institute on Aging, MD, USA; 16Evangelisches Krankenhaus Bielefeld GmbH, Bielefeld, Germany; 17Department of Neurology,
Weill Cornell Medical College, New York, NY, USA; 18Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool, United Kingdom; 19Department of Cardiovascular and
Metabolic Medicine, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, United Kingdom; 20Liverpool Heart and Chest Hospital, Liverpool, United Kingdom; 21Aalborg
Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark; 22Department of Experimental and Clinical Medicine, General Cardiology Division, University of
Florence and AOU Careggi, Florence, Italy; 23(CASSA representative): Milpark Hospital, Cardiology Unit, Johannesburg, South Africa; 24(APHRS representative): Saiseikai Kumamoto Hospital,
Kumamoto, Japan; 25University of Iowa Hospitals and Clinics, Iowa City Iowa, USA; 26Covenant Hospital, Waterloo, Iowa, USA; 27Mercy Hospital Mason City, Iowa, USA; 28School of Medicine,
Belgrade University, Serbia; 29Cardiology Clinic, Clinical Center of Serbia, Serbia; 30(APHRS representative): Waikato Clinical School, University of Auckland and Waikato Hospital, Hamilton, New
Zealand; 31Department of Pharmacology, School of Medicine, CIBERCV, Universidad Complutense, Madrid, Spain; 32Department of Electrophysiology, Heart Center Leipzig, Leipzig, Germany;
33
  Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark; 34Klinikum d. Universität München Campus, München, Germany; 35Chu De Poitiers, Service De Cardiologie, Poitiers,
France; 36Cardiology Department, Hospital Santa Cruz, Lisbon, Portugal; 37Yale University School of Medicine, Section of Cardiovascular Medicine, CT, USA; 38Taipei Veterans General Hospital,
Cardiology Division, Taipei, Taiwan; 39UCT Private Academic Hospital, Cape Town, South Africa; 40Centro Medico Docente la Trinidad, Cardiology Unit, Caracas, Miranda, Venezuela;
41
  Department of Health Sciences/Geriatrics, University of Oulu, Oulu, Finland; and 42Jagiellonian University Medical College, Cracow, Poland25412491276

Received 22 June 2022; accepted after revision 27 June 20222023



* Corresponding authors. Tel: +44 2087250439; fax: +39 2087253416. E-mail address: isavelie@sgul.ac.uk (IS); Tel: +39 055 2751821. E-mail address: stefano.fumagalli@unifi.it (SF)
© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse,
distribution, and reproduction in any medium, provided the original work is properly cited.
1250                                                                                                                                                                                                                                                 I. Savelieva et al.




Abstract                                         There is an increasing proportion of the general population surviving to old age with significant chronic disease, multi-
                                                 morbidity, and disability. The prevalence of pre-frail state and frailty syndrome increases exponentially with advancing
                                                 age and is associated with greater morbidity, disability, hospitalization, institutionalization, mortality, and health care
                                                 resource use. Frailty represents a global problem, making early identification, evaluation, and treatment to prevent
                                                 the cascade of events leading from functional decline to disability and death, one of the challenges of geriatric and




                                                                                                                                                                                                                                                                                 Downloaded from https://academic.oup.com/europace/article/25/4/1249/7036349 by Uniwersytet Jagiellonsky w Krakowie user on 05 August 2024
                                                 general medicine. Cardiac arrhythmias are common in advancing age, chronic illness, and frailty and include a broad
                                                 spectrum of rhythm and conduction abnormalities. However, no systematic studies or recommendations on the
                                                 management of arrhythmias are available specifically for the elderly and frail population, and the uptake of many ef­
                                                 fective antiarrhythmic therapies in these patients remains the slowest. This European Heart Rhythm Association
                                                 (EHRA) consensus document focuses on the biology of frailty, common comorbidities, and methods of assessing
                                                 frailty, in respect to a specific issue of arrhythmias and conduction disease, provide evidence base advice on the man­
                                                 agement of arrhythmias in patients with frailty syndrome, and identifies knowledge gaps and directions for future
                                                 research.
------------------------------------------------------------------------------------------------------------------------------------------------------------
Keywords                  European Heart Rhythm Association • Position paper • Consensus document • Frailty • Elderly • Frailty syndrome
                          • Frailty assessment • Frailty domains • Pre-frailty state • Elderly • Cachexia • Arrhythmias • Atrial fibrillation •
                          Ventricular tachycardia • Heart failure • Stroke • Cognitive impairment • Antiarrhythmic drugs • Anticoagulants •
                          Ablation • Pacemaker • Implantable cardioverter-defibrillator • Cardiac resynchronization therapy • Cardiac
                                                 resynchronization therapy-defibrillator




                                                                                                                                               Pacing for undocumented bradycardia ..........................................                                             1259
Table of contents                                                                                                                              Leadless pacing .........................................................................................                  1259
Abstract.................................................................................................................         1250   Ventricular arrhythmias..................................................................................                        1259
Introduction.........................................................................................................             1251      Ventricular premature beats and ventricular tachycardia ..........                                                            1259
Review of evidence...........................................................................................                     1251      Pharmacological management of VPBs and ventricular
Relationships with industry and other conflicts of interest............                                                           1251      tachycardia ......................................................................................................            1259
Definition, epidemiology, and associations of frailty..........................                                                   1252         Beta-blockers and non-dihydropyridine calcium
   Definition and epidemiology ...................................................................                                1252         antagonists..................................................................................................              1260
   Pre-frail state..................................................................................................              1252         Mexiletine and lidocaine.......................................................................                            1260
                                                                                                                                               D, L-Sotalol..................................................................................................             1260
   Frailty vs. clinical complexity ...................................................................                            1252
   Major clinical conditions related to frailty .........................................                                         1252         Amiodarone...............................................................................................                  1260
       Anorexia and malnutrition..................................................................                                1252         Other antiarrhythmic drugs................................................................                                 1260
       Sarcopenia ..................................................................................................              1253         When to intervene? ...............................................................................                         1260
       Heart failure ..............................................................................................               1253      Drug-induced ventricular arrhythmias ................................................                                         1260
       Cancer..........................................................................................................           1253         Treating proarrhythmias ......................................................................                             1261
       Falls................................................................................................................      1253      Ablation for ventricular arrhythmias ...................................................                                      1261
       Neurological conditions including cognitive impairment and                                                                           ICD: indications, selection, and outcome ..........................................                                           1261
       dementia .....................................................................................................             1254      ICD programming in frail older patients............................................                                           1262
       Multiple comorbidities and polypharmacy ...................................                                                1254      Subcutaneous ICDs.....................................................................................                        1262
       Electrolyte disorders, renal impairment, metabolic issues ....                                                             1254      Lead failure management..........................................................................                             1262
Assessment of frailty and frailty scores ...................................................                                      1255   Heart failure and cardiac resynchronization therapy ........................                                                     1263
Pathophysiology overview of biological changes associated with                                                                              Definition and assessment of frailty in HF ........................................                                           1263
frailty .......................................................................................................................   1256      CRT: indications, optimization, follow-up .........................................                                           1263
   Frailty and age-related electrical and structural changes of the                                                                      Device replacement, upgrade/downgrade, and deactivation at end
   heart and vasculature .................................................................................                        1256   of life.......................................................................................................................   1263
   Interaction between ageing cardiovascular system and frailty..                                                                 1256   Supraventricular arrhythmias .......................................................................                             1264
Clinical pharmacology .....................................................................................                       1256   Atrial fibrillation .................................................................................................            1264
   Metabolism......................................................................................................               1256      Rate vs. rhythm control management.................................................                                           1264
   Adverse effects..............................................................................................                  1258      Stroke prevention ........................................................................................                    1265
Bradyarrhythmias ..............................................................................................                   1258         General principles ...................................................................................                     1265
   Drug-induced bradycardia........................................................................                               1258         Antithrombotic management in old and frail..............................                                                   1265
   Intraventricular conduction abnormalities ........................................                                             1258         Left atrial appendage occlusion.........................................................                                   1267
   Pacing: indications, mode selection, programming, follow-up,                                                                             Ablation: indications and outcome.......................................................                                      1267
   remote monitoring......................................................................................                        1258      Silent arrhythmias and screening for AF ............................................                                          1268
Expert consensus document on the management of arrhythmias in frailty syndrome                                                                                                                        1251


Stroke as a frailty component and specific characteristics in the                                                                   Therefore, this consensus document will explain the biology of
very elderly...........................................................................................................   1269   frailty, common comorbidities, methods of assessing frailty, issues
   Ischaemic vs. haemorrhagic stroke risk ..............................................                                  1269   specific to various types of arrhythmias and provide advice on the
   Implications for acute management and chronic                                                                                 management of arrhythmias in elderly and frail patients as well as
   anticoagulation...............................................................................................         1269
                                                                                                                                 identify knowledge gaps and directions for future research. The
Orthostatic hypotension and syncope syndrome ..............................                                               1269
                                                                                                                                 document is targeted at primary and secondary care practitioners
   Carotid hypersensitivity syndrome.......................................................                               1269
                                                                                                                                 involved in treating older pre-frail and frail patients with cardiac ar­
   Orthostatic intolerance syndrome.......................................................                                1270




                                                                                                                                                                                                             Downloaded from https://academic.oup.com/europace/article/25/4/1249/7036349 by Uniwersytet Jagiellonsky w Krakowie user on 05 August 2024
   Investigations and management .............................................................                            1270   rhythmias, conduction disease, and cardiac implanted electronic
Improving patient outcome: specific consideration ...........................                                             1271   devices.
   Quality of life..................................................................................................      1271
   Care models ...................................................................................................
   Development of a specialist team and aftercare............................
                                                                                                                          1271
                                                                                                                          1271
                                                                                                                                 Review of evidence
   Digital technology and eHealth..............................................................                           1271   This consensus document was prepared by the Task Force
Acknowledgement............................................................................................               1271   with representation from European Heart Rhythm Association
Supplementary material..................................................................................                  1272   (EHRA), Heart Rhythm Society (HRS), Asia Pacific Heart
References............................................................................................................    1272
                                                                                                                                 Rhythm Society (APHRS), Latin America Heart Rhythm Society
                                                                                                                                 (LAHRS), and Cardiac Arrhythmia Society of Southern Africa
                                                                                                                                 (CASSA). The document will be peer-reviewed by official exter­
Introduction                                                                                                                     nal reviewers representing EHRA, HRS, APHRS, LAHRS, and
                                                                                                                                 CASSA.
Cardiac arrhythmias become more common and embrace a                                                                                Members of the Task Force were asked to perform a detailed lit­
broad spectrum of rhythm and conduction abnormalities with ad­                                                                   erature review, weigh the strength of evidence for or against a par­
vancing age and chronic illness. According to the World Health                                                                   ticular treatment or procedure, and include estimates of expected
Organization, in 2019, 1 billion of people worldwide were aged                                                                   health outcomes where data exist. Patient-specific modifiers, co­
60 years and older, with this number set to double by 2050.1 The                                                                 morbidities, and issues of patient preference that might influence
greatest rise is in persons aged 80 years or older, with expected up­                                                            the choice of particular investigations or therapies were considered,
surge by four-fold to 434 million worldwide. Concurrently, there is                                                              as are frequency of follow-up and cost-effectiveness. In controversial
an increasing proportion of the general population surviving with                                                                areas, or regarding the issues without evidence other than usual clin­
significant chronic disease and disability.                                                                                      ical practice, a consensus was achieved by agreement of the expert
   Ageing is frequently characterized by the coexistence of several                                                              panel after discussions.
comorbid conditions, often reciprocally interacting to produce a                                                                    Consensus statements are based upon strength of evidence and
greater than additive negative impact on health status. Pre-frail                                                                consensus as outlined in Table 1.
state and frailty, mainly in association with old age and multi-
morbidity, is increasingly seen among patients with cardiovascular
disease and arrhythmias. Management of patients with frailty
                                                                                                                                 Relationships with industry and
syndrome has been deliberated in specific settings such as acute                                                                 other conflicts of interest
cardiac and critical care,2 heart failure (HF)3 as well as in general
                                                                                                                                 It is EHRA/European Society of Cardiology (ESC) policy to sponsor
cardiology.4 Timely and appropriate identification and assessment
                                                                                                                                 position papers and guidelines without commercial support, and all
of the reduction in physiological reserves and frailty, which can
                                                                                                                                 members volunteered their time. Thus, all members of the writing
be done using the dedicated methods and definitions (see Section
‘Assessment of frailty and frailty scores’) or employing simplified
tools based on the characterization of single domains of frailty or
                                                                                                                                  Table 1 Categories of consensus statements
self-report questionnaires is useful in guiding the individual ap­
proach to patient management and ensuring safe and effective                                                                       Consensus            Definition
therapies.                                                                                                                         statement
                                                                                                                                   ...............................................................
   However, no systematic studies or recommendations on the manage­
ment of arrhythmias in the frail population are available, not in the least                                                        ‘Should do this’     Scientific evidence that a treatment or
because these patients have been excluded from major clinical trials,                                                                                     procedure is beneficial and effective, or
whereas lack of the awareness about the safety and efficacy of antiar­                                                                                    is strongly supported by author’s
rhythmic therapies accounts for withholding effective pharmacological                                                                                     consensus.
                                                                                                                                   ‘May do this’        General agreement and/or scientific
(e.g. anticoagulation) or non-pharmacological (e.g. ablation) interventions.
Surveys have revealed a wide variation among physicians in understanding                                                                                  evidence favour the usefulness/efficacy
of what constitutes frailty syndrome and highlighted the lack of guidance                                                                                 of a treatment or procedure
                                                                                                                                   ‘Do not do this’     Scientific evidence or general agreement
on the use of the variety of available therapies. Whereas frailty is not syn­
onymous with ageing and the high heterogeneity in older age populations                                                                                   not to use or recommend a treatment
should be acknowledged, practitioners treating arrhythmias will more and                                                                                  or procedure
more encounter patients who are frail.
1252                                                                                                                                            I. Savelieva et al.



group as well as reviewers have disclosed any potential conflict of                from frailty with effective rehabilitation interventions. Frequent and/
interest in detail (see Appendix I).                                               or long-term hospitalization associated with sarcopenia and weak­
                                                                                   ness is a major risk factor for transitioning from robust to pre-frail
Definition, epidemiology, and                                                      and subsequently developing frailty.
                                                                                       However, the hypothesis that reducing risk factors or enhancing pro­
associations of frailty                                                            tective factors may prevent or delay age-associated frailty has not been
                                                                                   formally tested in appropriately sized randomized controlled trials. There




                                                                                                                                                                      Downloaded from https://academic.oup.com/europace/article/25/4/1249/7036349 by Uniwersytet Jagiellonsky w Krakowie user on 05 August 2024
Definition and epidemiology                                                        is general consensus that frailty derives from the acceleration of biological
Frailty identifies a syndrome characterized by high biological vulner­             ageing and that as our understanding of the biology of ageing progresses,
ability, decreased physiologic reserve, and reduced capacity to resist             effective prevention and treatment strategies will be developed.
stressors, due to multiple impairments in inter-related systems, lead­
ing to reduced homeostatic reserve.5
   The prevalence of frailty has been estimated to be 12% (10–15%) in
                                                                                   Knowledge gaps
the community, rising to 45% (27–63%) in the non-community cohorts,6               • Better definition of pre-frail state and tools (derived from the frailty as­
with higher rates in women and the highest in individuals aged 85 years              sessment tools or specifically developed) for its evaluation are required.
and older.7,8 Multiple comorbidities are associated with a more than               • Epidemiology of pre-frail state needs to be prospectively studied.
two-fold increase in the prevalence of frailty (up to 63–81%). In analysis         • The driving risk factors associated with gender differences in the in­
including 240 studies from 62 countries representing 1 755 497 partici­              cidence and prevalence of pre-frailty and frailty should be explored.
pants, the prevalence of frailty in studies using physical frailty measures        • It is still unknown whether a global care plan that is triggered by the diag­
                                                                                       nosis of frailty improves objective health outcomes and whether the pro­
was 12% compared with 24% for those using a frailty index (FI).9 For pre-
                                                                                       cesses which lead to frailty can be attenuated or reversed is also unknown.
frailty, this was 46% and 49%, respectively. Physical frailty was more com­
monly identified in women than men (15% vs. 11%). Combination of
                                                                                   •   Physician’s awareness of the importance of evaluation for the pre-frail
                                                                                       state and identification of modifiable components with appropriate
multiple comorbidities with frailty phenotype substantially increased long-            interventions needs to be improved.
term mortality risk in septuagenarian men [hazard ratio (HR) 2.93, 95%
confidence interval (CI) 2.10–4.07].10
   Two different conceptual models of frailty have been proposed.11,12             Frailty vs. clinical complexity
According to model proposed by Fried et al.,11 a cascade of events—                Ageing is associated with progressive loss of biological homeostatic
from molecular oxidative stress to DNA damage accelerating cellular                and functional reserve that puts an older individual at high risk of de­
senescence—leads to endocrine and immune system dysregulation,                     veloping adverse health outcomes, including multiple comorbidities,
which results in the development of a frailty phenotype, consisting                mobility loss, disability, cognitive impairment and eventually becomes
of reduced muscle strength, body weight, and gait speed, and of in­                so severe to be incompatible with life. While part of this decline of
creased fatigue or inability to perform demanding activities. An alter­            health and functional status is directly attributable to diseases, in
native model by Mitnitski et al.12 describes the cumulative deficit                some specific individuals the accumulation of damage is so pervasive
model defines frailty not as a specific syndrome, but rather as an                 and multisystemic that it is impossible to recognize a single cause and,
age-related state of additive medical and functional problems.                     therefore, clinicians and scientists define them as frail.
Despite theoretical differences, the two models have much in com­                     Frailty may have unpredictable trajectories and coexists with
mon and are able to identify older individuals at higher risk of events.13         other geriatric conditions, such as multiple comorbidities and disabil­
                                                                                   ity.17,18 Ageing is associated with frailty, multiple comorbidities and
Pre-frail state                                                                    disability, and these conditions are largely overlapping. Frailty and
The concept of pre-frail state is less well developed and supported by epi­        complexity are sometimes used synonymously, though the term
demiological and clinical data, and the definitions are vague. Pre-frail state     ‘complexity’ should be reserved to indicate the presence of multiple
or intermediate frailty phenotype is identified if one or two out of five cri­     comorbidities with its implicit burden of polypharmacy.19 In this re­
teria based on the Fried model11 or as the number of accumulated deficits          spect, complexity may be a component or, better, may contribute to
based on the FI.14 It is not uncommon to refer to pre-frailty as a clinically      frailty but does not identify with it.
silent phase preceding frailty or a condition that predisposes to frailty.15
    The exact rates of pre-frailty are difficult to establish. It has been esti­   Major clinical conditions related to frailty
mated that the prevalence of the pre-frailty state in individuals aged             Anorexia and malnutrition
65 years and older may range between 18.8% and 50.9%. In a recent                  Anorexia (loss of appetite or inability to eat), is frequently observed in
meta-analysis in the community-dwelling older adults who were robust               the older individuals promoting malnutrition and leading through sarco­
at baseline 30.9% became pre-frail during a median follow-up of 2.5 years          penia and muscle loss to disability and higher morbidity and mortality.
(the incidence rate of 150.6 per 1000 person-years), whereas among                 The anorexia of ageing affects approximately 20% of the older popula­
non-frail (robust and pre-frail at baseline) individuals, 13.6% progressed         tion and is higher in hospitalized elderly patients (23–62%) and long-
to frailty over a medial follow-up of 3 years (the incidence rate of 43.4          term nursing home residents (up to 85%).20 Advanced age often contri­
per 1000 person-years).16 The pre-frailty incidence rates were significant­        butes to this cascade through different pathways.20 Older patients are
ly higher in women than men (173.2 vs. 129.0 per 1000 person-years).               less sensitive to the action of ghrelin, the hunger hormone, because of
    The clinical importance of the pre-frail state concept as a transi­            the increased concentration of insulin and leptin, the satiety hor­
tional state between robust and frail lies in the possibility of reversal          mones.21 Many conditions that are common in older persons affecting
Expert consensus document on the management of arrhythmias in frailty syndrome                                                                         1253


nutritional balance: cancer, HF, chronic obstructive pulmonary disease,         Cancer
chronic kidney disease (CKD), gastrointestinal disorders, mal-                  Frailty is particularly important in the management of cancer patients,
absorption syndrome, Parkinson’s disease—all determine anorexia                 who may have mortality rates as high as 80%, as cancer and related
and/or increased energy expenditure. Psychiatric disorders such as de­          therapies may both greatly challenge patient’s physiologic reserve,25
pression, cognitive impairment, and dementia also contribute to the re­         when a pre-frail or a clearly frail status can be found in more than
duced appetite. Commonly prescribed medications, swallowing and                 50% of cancer cases.25,26 Specific oncologic adverse outcomes pos­
chewing difficulties, decline of senses, living alone or in a nursing           sibly related to frailty are chemotherapy side effects,27 disease recur­




                                                                                                                                                              Downloaded from https://academic.oup.com/europace/article/25/4/1249/7036349 by Uniwersytet Jagiellonsky w Krakowie user on 05 August 2024
home, and other social or economic problems may negatively influence            rence or progression, and death.25 Registry data show that cancer
the nutritional profile. Despite their importance, anorexia and malnutri­       prognosis is associated with frailty-related conditions such as weight
tion are not routinely assessed in everyday clinical practice.                  loss, reduced gait speed, major depression, and institutionalization in
                                                                                nursing home.28 The presence of frailty should promote multidiscip­
   Consensus statement                                                          linary decision-making and individually tailored therapeutic ap­
                                                                                proaches aimed at preserving health-related quality of life.
  • Routine assessment of anorexia and malnutrition and
      appropriate interventions should be undertaken in all                        Consensus statement
      at-risk older persons or other at-risk cohorts.
                                                                                  • Early evaluation for the signs of frailty and timely
                                                                                      recognition of the pre-frail state will enable interventions
                                                                                      that may deter progression to frailty and preserve quality
Sarcopenia
                                                                                      of life, particularly in treatable and non-aggressive cancers.
Sarcopenia, the age-dependent loss of both the muscle mass and muscle
strength and function, is a common condition associated with frailty and
adverse health outcomes.22 After the age of 70 years, the average muscle
loss amounts to 15% per each decade. The prevalence of sarcopenia in            Falls
the community is 1–29% rising to 14–33% in the long-term care. Aging,           Frail older adults are likely to experience recurrent falls. In the
anorexia, malnutrition, age-related hormonal changes, sedentary life­           meta-analysis of 102 130 community-dwelling individuals aged
style, and limited mobility mark decreased anabolism, whereas disease           65 years and older, frail patients had a 2.5-fold increased risk of falls,
state, inflammation, oxidative stress, and mitochondrial dysfunction de­        whereas those in the pre-frail state had 1.5-fold increased risk of fall
termine increased catabolism leading to the development of sarcopenia.          compared with robust individuals.29 Frailty-induced falls incur a low
Sarcopenia should be considered when implementing preventative and              quality of life in older adults and increase risk of bone fractures, hos­
therapeutic interventions (e.g. optimized nutrition, elimination of vitamin     pitalization, and death as well as burden on their carers.
D deficiency, and physical exercise) aiming at reversing physical frailty at        Frail patients with suspected arrhythmias should be assessed for falls
its initial stage and slowing or halting the progressive decline towards dis­   risk. Modifiable risk factors for falls outwit environmental hazards (loose
ability and dependency.22                                                       rugs, steps, etc.) include gait and balance impairment, cognitive impair­
                                                                                ment, depression, polypharmacy, psychotropic drugs, cardiovascular
Heart failure                                                                   drugs, visual abnormalities (poor visual acuity and impaired contrast sen­
Frailty is particularly common in HF: in a meta-analysis, a 47.4%               sitivity), orthostatic hypotension, low blood pressure (BP), arrhythmias
prevalence of frailty in patients with HF was estimated using multidi­          (most commonly bradyarrhythmias), urinary incontinence, prior falls,
mensional assessment tools.23 The prevalence of frailty in patients             and fear of falling.30 All identified risk factors should be modified.
with HF is independent of age, suggesting a more complex inter­                     Falls are categorized as accidental, i.e. a slip or trip or non-
action between the two syndromes and the progressive decline in                 accidental. The latter are more likely to be attributable to cardiovas­
physiological reserve. The mechanisms linking frailty to HF are multi-          cular abnormalities, particularly hypotensive disorders or arrhyth­
factorial, with inflammatory markers, impaired skeletal muscle func­            mias. In practice, the distinction is less clear unless a fall has been
tion due to mitochondrial dysfunction, decreased capillary density,             witnessed (not the case in up to 50% of events) and/or the older per­
and adipose tissue infiltration potentially involved.3 Conversely, age­         son has a clear recall of events.31
ing, frailty, comorbidities, and immobility due to hospitalization, may             In older fallers, a detailed cognitive assessment will assist in deter­
all contribute to increase the severity and accelerate the progression          mining whether the patient’s recall is unreliable, i.e. recall of pro­
of HF leading to increased risk of morbidity and mortality.24                   drome, circumstances of fall, loss of consciousness, palpitations,
                                                                                chest pain, post-event characteristics. Such falls should be investi­
   Consensus statements                                                         gated as per syncope guidelines (Figure 1).32
                                                                                    In older frail individuals, orthostatic intolerance manifesting as
  • Evaluation for frailty should be included into routine                      orthostatic hypotension due to pharmacotherapy with antihyperten­
      clinical management of patients with heart failure.                       sive and antianginal agents, and sedatives and deconditioning is a
  • Early intervention targeting modifiable components of                       common cause of falls. Other causes are primary, secondary auto­
      frailty is important in improving prognosis and quality of                nomic failure, hypovolemia, and anaemia.33 Sarcopenia and conse­
      life in heart failure.                                                    quent deconditioning are contributory causes in frail persons.
                                                                                    In one-quarter to one-third of patients with falls, particularly when
                                                                                long-term continuous rhythm monitoring is employed, falls are
1254                                                                                                                                I. Savelieva et al.



                                                                        may also increase the risk of falls through different mechanisms.
                                                                        Psychotropic drugs are related to fall injuries, hospitalization,
                                        Falls in adults                 and death.38
                                                                            Dementia and cognitive impairment play a significant role in this
                                                      Accidental
                                                                        context and are associated with an increased risk of falls. Since pre­
                              Non-accidental                            vention of future falls is a major objective of treatment, there is par­
                                                     “Slip or trip”
                                                                        ticular interest in the effect of cognitive training on the future risk of




                                                                                                                                                          Downloaded from https://academic.oup.com/europace/article/25/4/1249/7036349 by Uniwersytet Jagiellonsky w Krakowie user on 05 August 2024
                                                                        falls. As recently shown in meta-analyses of randomized trials, com­
            Unexplained Fall,                  Explained
             “syncope likely”             i.e., impaired gait/          bined exercise and cognitive training improved balance in mild cogni­
                                          balance, cognitive            tive impairment39 and physical exercise had a significant effect in
                                         status, environment
                                                 hazard                 preventing falls in older adults with cognitive impairment.40
          Same evaluation as for
           unexplained syncope                                              Another important aspect is the fear of falling in frail patients.
                                                                        Recent studies demonstrated an independent association of frailty
  Figure 1 Flow diagram for the identification of unexplained falls.    with fear of falling, and cognitive behavioural therapies may improve
  Reproduced from Brignole M, et al. 2018 ESC Guidelines for the        fear of falling.41
  diagnosis and management of syncope. European Heart Journal,
  2018;39(21):1883–1948, by permission of Oxford University                Consensus statements
  Press and the European Society of Cardiology (ESC).32
                                                                          • Patients treated with psychotropic drugs should be
                                                                              monitored for falls.
directly linked with arrhythmias—most commonly bradyarrhythmia,           • Exercise and cognitive training may improve balance and
asystole, and tachy-brady forms of atrial fibrillation (AF).34–36             prevent frailty progression in patients with an early stage
Antiarrhythmic medications may potentiate orthostatic intolerance,            of cognitive impairment.
increase risk of bradycardia, contribute to other falls risk factors,
such as impairment of attention/concentration, sleep impairment,
electrolyte disturbance, or visual impairment.
                                                                        Multiple comorbidities and polypharmacy
                                                                        Cardiovascular Health Study demonstrated a strong association of
   Consensus statements                                                 frailty with a number of chronic diseases including cardiovascular
                                                                        and pulmonary diseases and diabetes: 33% of the frailty subjects
  • Assessment for risk factors for falls is beneficial in all frail    had 3–4 chronic diseases, 27% two, and 8% >5 concomitant condi­
      patients.                                                         tions.11 Multiple comorbidities in frailty subjects may not only aggra­
  •   Non-accidental falls which are unexplained should be              vate frailty phenotypes, but result in the increased risk of
      investigated as per syncope in accordance with the 2018           polypharmacy which has repeatedly been shown to be a marker
      ESC Guidelines for the diagnosis and management of                of adverse clinical outcome. The French study of a cohort aged
      syncope.                                                          >70 years revealed that the mean number of drugs prescribed in­
  • In patients with orthostatic intolerance, precise details of        creased with increasing frailty from 4.6 in non-frail subjects to 6.1
      the pharmacotherapy, including non-cardiac medication             in pre-frail, 7.1 in frail, and 7.5 in dependent individuals.42
      should be collected.                                              Importantly, frailty and excessive polypharmacy with >10 drugs
  • In individuals with low blood pressure and/or orthostatic           were independent risk factors for mortality, and the combination
      hypotension/intolerance, medications which lower blood            multiplied the mortality risk for 2.6 years by 6.30. HF, renal failure,
      pressure should be used with care and physicians could            AF, dementia, and cancer were among the most common comorbid­
      evaluate possible benefits deriving from medication               ities recognized by physicians as associated with frailty.43
      withdrawal.
                                                                        Electrolyte disorders, renal impairment, metabolic issues
  • Falls risk should be monitored in patients prescribed               Chronic hyponatremia is the most common electrolyte disorder in
      antiarrhythmic medications.
                                                                        the elderly. It is caused mainly by drugs such as diuretics and antide­
  • Antiarrhythmic drugs which cause minimal effect on blood            pressants and by syndrome of inappropriate antidiuretic hormone
      pressure are preferred.
                                                                        secretion. Though often mild and asymptomatic, it aggravates frailty
                                                                        phenotypes leading to cognitive disorders and gait impairments and
                                                                        contributes to osteoporosis leading to bone frailness, thus predis­
Neurological conditions including cognitive impairment                  posing the patients to falls and hip fractures.44 CKD is common in
and dementia                                                            ageing. Sarcopenia increases progressively along with renal impair­
Frailty and falls are more common in age-related neurological dis­      ment in CKD, being highest in dialysis patients. Prevalence of frailty
orders such as stroke, Parkinson’s disease, dementia, or epi­           has been documented in 7% of the elderly, 14% of CKD patients
lepsy.37 The proportion of ‘fallers’ is higher even in subgroups        not requiring dialysis, and 42% of those on haemodialysis.45 Frailty
with least fall-associated neurological diseases such as tinnitus       in haemodialysis patients is associated with 2.6 times greater risk
and headache. Medical treatment, including that for dementia,           of mortality and 1.4 times more hospitalization, independent of
Expert consensus document on the management of arrhythmias in frailty syndrome                                                                                 1255


age, sex, comorbidity, and disability.46 Of the metabolic issues, insulin
                                                                                  Table 2 Diagnostic criteria used for the diagnosis of
resistance significantly increases with age, and is considered as a ma­
                                                                                  frailty (Fried criteria)
jor risk factor for many age-related diseases. Insulin resistance plays
an important mediating role in the frailty cycle including chronic in­             Measure               Definition
                                                                                   ...............................................................
flammation, reduced skeletal muscle metabolism, cognitive decline
and sarcopenic obesity. Interventions aimed at correcting insulin re­              Weight loss           Lost 4.5 kg or more unintentionally over the last
sistance therefore may have a critical role in preventing or slowing                                       year




                                                                                                                                                                         Downloaded from https://academic.oup.com/europace/article/25/4/1249/7036349 by Uniwersytet Jagiellonsky w Krakowie user on 05 August 2024
the downward spiral of frail older persons.47                                      Exhaustion            Self-report of either ‘felt that everything I did was an
                                                                                                           effort’ and/or ‘could not get going’ in the last
                                                                                                            week
Assessment of frailty and frailty                                                  Low physical          Self-report, equivalent to <90 kCal in women and
                                                                                      activity              <128 kCal in men
scores                                                                             Slow walking          4 m at usual pace:
Frailty is considered an age-related syndrome with unknown patho­                                        speed <0.76 m/s for height <159 cm in women and
physiology, operationally defined as loss of functional reserve in mul­                                     <173 cm in men or speed <0.80 m/s for height
tiple physiologic systems, lack of resilience to everyday stressors and                                     >159 cm in women and >173 cm in men
elevated risk for a range of adverse health outcomes. Criteria were                Weakness              Grip strength
developed to identify frail older persons in spite of the substantial                                    Women: <17 kg for BMI <23 kg/m2; <17.3 kg for
heterogeneity of this population.                                                                           BMI 23.1–26 kg/m2; <18 kg for BMI 26.1–29 kg/
   The most popular set of criteria has been developed using data                                         m2; and <21 kg for BMI >29 kg/m2
from the Cardiovascular Health Study.11 Building on the conceptual                                       Men: <29 kg for BMI <24 kg/m2; <30 kg for BMI
framework that frailty derives from a mutually exacerbating cycle of                                        24.1–26 kg/m2; <30 kg for BMI 26.1–28 kg/m2;
negative energy balance, sarcopenia, and diminished strength and tol­                                       <32 kg for BMI >28 kg/m2
erance for exertion, frailty can be defined according to the following
criteria: unintentional weight loss, feeling of exhaustion, muscle weak­          Please note diagnostic thresholds for different criteria were modified for different
                                                                                  population and different studies. At least 2/5 positive criteria defines pre-frailty
ness, slowness while walking, and low levels of activity, ascertained by a        and >3/5 criteria defines frailty.
combination of self-reported and performance-based measures                       BMI, body mass index.
(Table 2). Individuals who have three or more of these criteria should
be considered ‘frail’, and those with two of these criteria should be
                                                                                 alternative approaches to care that results in better clinical outcomes
considered ‘pre-frail’. The predictive validity of these criteria toward
                                                                                 remains uncertain.
different outcomes has been overwhelmingly demonstrated in hun­
dreds of manuscripts published in and outside the geriatric literature.
   The second approach is the FI which is calculated as the ratio be­            Knowledge gaps
tween the number of deficits detected and the total number of deficits
considered, which may be quite variable and include diseases, physical           • Inconsistency in assessment of frailty by the existing tools, with the
                                                                                    physical function and mobility being the only consistent domain,
and cognitive impairments, psychosocial risk factors, and geriatric syn­
                                                                                    needs to be addressed.
dromes such as falls, delirium, and urinary incontinence (Table 3).48
The FI is a strong predictor of adverse health outcomes and allows ro­
bust clinical inferences.49,50 The FI categorizes older individuals in several    Table 3 Short version of the frailty index
classes, from ‘robust’ to ‘severely frail’. Since FI can be generated from
almost any set of health-related variables, this tool is highly flexible            (1)   Non-independent functional status
and can be adapted to the large number of situations and harmonized                 (2)   History of diabetes mellitus
across research projects and clinical centres.                                      (3)   History of either chronic obstructive pulmonary disease or
   There are also self-report questionnaires or instruments based on                      pneumonia
the assessment of single performances (i.e. single domains of frailty).             (4)   History of congestive HF
   The most effective clinical use of frailty has been the stratification           (5)   History of myocardial infarction
of patients to verify what medical interventions are beneficial in this             (6)   History of percutaneous coronary intervention, cardiac
special population or whether alternative approaches should be con­                       surgery, or angina
sidered. Frail older persons should not be excluded a priori from any               (7)   Hypertension requiring the use of medications
type of treatment, and decision-making should be treatment-specific                 (8)   Peripheral vascular disease or rest pain
and based on scientific evidence. Specifically, where treatment of dif­             (9)   Impaired sensorium
ferent types of cardiac arrhythmias have the same beneficial effects in            (10)   Transient ischaemic attack or cerebrovascular accident
frail and non-frail older persons is unknown.                                             without residual deficit
   Overall, the definition of frailty appears to be a powerful tool to             (11)   Cerebrovascular accident with deficit
establish prognosis, the risk of complication after surgery or aggres­
                                                                                  The index is calculated as (total number of variables present)/(total number of
sive medical interventions as well as forecasting future health care re­          variables assessed). A score ≥0.36 indicates frailty.
source utilization. Whether the identification of frailty triggers
1256                                                                                                                                         I. Savelieva et al.



                                                                                (already before the appearance of clinical cardiovascular disease)
• The need for disease-specific frailty assessment tools should be as­          for frailty, particularly in younger individuals.52
    sessed and methodology for development and validation of such
    tools should be defined.                                                       The extent of cardiovascular ageing which is very variable among
                                                                                older people of the same age, will be a major modulator of functional
                                                                                status, and the degree of functionality and autonomy especially after
Pathophysiology overview of                                                     the age of 80 years.
                                                                                   Older individuals with marked frailty will have a more pro­
biological changes associated with




                                                                                                                                                                   Downloaded from https://academic.oup.com/europace/article/25/4/1249/7036349 by Uniwersytet Jagiellonsky w Krakowie user on 05 August 2024
                                                                                nounced evolution of cardiovascular disease. Thus, for the same le­
frailty                                                                         vel of cardiac dysfunction a frail person will have a more
                                                                                pronounced clinical impact than a more robust person. This is
Frailty is a syndrome characterized by decreased reserve and resist­            very often observed in heart failure patients in whom the presence
ance to stressors, causing vulnerability to adverse outcomes such as            of frailty and sarcopenia is synergistic with the consequences of
morbidity, iterative hospitalizations, loss of autonomy and death.
                                                                                heart disease and amplifies clinical signs such as fatigue, dyspnoea,
Frailty can result from decline across one or more physiologic sys­             and cachexia. In addition, the presence of frailty will increase the
tems. Schematically, we can distinguish four major domains of frailty:          risk of medication-related adverse effects. Clinical studies have
• Physical, mainly related to loss of muscle mass and function and re­          shown that the severity of frailty modifies the benefits/risk ratio
  duced physical performance.                                                   of several medical and surgical cardiovascular therapies.
• Cognitive, due to cognitive decline and/or dementia.
• Psychological, mainly related to depressive manifestations.                      Consensus statements
• Social, related to isolation and absence of social activities.
                                                                                  • It is important to assess the frailty level in older people
                                                                                      with cardiovascular disease in order to estimate the risk of
Frailty and age-related electrical and
                                                                                      functional decline, loss of autonomy, and death.
structural changes of the heart and
vasculature
                                                                                  • Based on frailty assessment, the risk/benefit balance of
                                                                                      therapeutic strategies may be better identified.
Cardiovascular ageing is the result of alterations of the structure and
function of:
                                                                                  • Frailty assessment is necessary in the frame of the holistic
                                                                                      management of older patients with cardiovascular
•   Arteries: endothelial dysfunction, intima-media thickness, arterial wall          diseases especially those with multiple comorbidities and
    calcifications, alterations in the extracellular matrix.                          polypharmacy.
•   Heart: wall hypertrophy and fibrosis, cavities dilation, valve calcifica­
                                                                                  • Using age as the main criterion for the provision of health
    tions and degeneration, changes in cardiac muscle cell contractility.             and social care services for older people should be
   All these alterations concern the totality of the cardiovascular                   avoided.
components (large and small arteries, coronary circulation, myocar­
dium, valves, conductive system) and are the pathophysiological
background of peripheral vasoconstriction, central artery stiffness,            Knowledge gaps
cardiac diastolic and systolic dysfunction. Acute and chronic manifes­
tations of these alterations are very frequent in the elderly, such as
                                                                                • Further research is needed to identify biomarkers that may be used
                                                                                   for the assessment of interaction between ageing, frailty, and cardio­
systolic hypertension, ischaemic heart disease, arrhythmias, valvular              vascular disease and outcomes.
heart disease, stroke, and acute and chronic HF.


Interaction between ageing                                                      Clinical pharmacology
cardiovascular system and frailty                                               Normal ageing produces physioflogical changes which affect the
Frailty and pre-frailty have been shown to be associated with any               pharmacokinetics (absorption, distribution, metabolism, and excretion)
type of cardiovascular disease, with an HR of 1.70 (95% CI: 1.18–               and pharmacodynamics of antiarrhythmic drugs (AADs) (Table 4).53–56
2.45) and 1.23 (95% CI: 1.07–1.36), respectively, compared with
the robust individuals.51                                                       Metabolism
   The combination of age-related arterial and cardiac alterations and          The plasma concentrations of some AADs (propranolol, verapamil)
their interactions (cardiac-artery coupling) are responsible for the            increase due to a decrease in their first-pass metabolism. The in­
above-mentioned cardiovascular diseases and also contribute to                  crease in body fat increases the volume of distribution (Vd) and
the development of other age-related degenerative diseases and syn­             the half-life of lipophilic drugs (amiodarone) and the decrease in total
dromes such as dementia, sarcopenia, renal failure, leading to frailty          body water reduces the Vd and increases the serum concentrations
and loss of autonomy. Ageing, frailty, and cardiovascular disease are           of hydrophilic drugs (digoxin). The decrease in albumin plasma levels
linked by multiple mechanisms and share several biomarkers includ­              increases the free-active fraction of AADs.
ing inflammation and oxidative stress biomarkers, natriuretic pep­                 Most AADs are biotransformed in the liver by CYP2D6 (flecai­
tides and troponins, and markers of CKD.52 Some cardiovascular                  nide, metoprolol, mexiletine, propafenone, vernakalant), CYP3A4
risk factors such as obesity are important long-term risk factors               (amiodarone, diltiazem, dronedarone, quinidine, verapamil) and
Expert consensus document on the management of arrhythmias in frailty syndrome                                                                                                                                                                                              1257



 Table 4 Age-associated changes in pharmacokinetics and pharmacodynamics

  Pharmacokinetic changes
  ...........................................................................................................................................
                                       Physiological change                                                        Pharmacokinetic effect                                                                  Drugs affected
  ...........................................................................................................................................
  Absorption                           • ↓ gastric acid production and                                             • antiacids, laxatives can ↓ drug absorption, • oral bioavailability of diltiazem,




                                                                                                                                                                                                                                                                                       Downloaded from https://academic.oup.com/europace/article/25/4/1249/7036349 by Uniwersytet Jagiellonsky w Krakowie user on 05 August 2024
                                              empting                                                                    anticholinergic drugs, propulsive drugs,                                                 propranolol, verapamil
                                       •      ↓ splanchnic blood flow, motility and                                      opioids—can induce OIBD (opioid induced
                                              absorption surface                                                         bowel dysfunction)
                                       •      ↓ first-pass metabolism
  Distribution                         • ↓ cardiac output and tissue
                                              perfusion, peripheral oedema
                                              increase Vd, loop diuretics eg
                                              furosemide can decrease Vd
                                       • ↓ muscle mass
                                       • ↑ body fat                                                                • Vd of highly lipophilic drugs                                                         • Vd of highly lipophilic drugs:
                                                                                                                                                                                                                  amiodarone, dronedarone,
                                                                                                                                                                                                                  lidocainne, verapamil
                                       •      ↓ extracellular and total body water                                 •     ↓ Vd of hydrophilic drugs                                                         • digoxin plasma levels, hydrophilic
                                                                                                                                                                                                                  antiarrhytmic drugs
                                       • ↓ plasma albumin,                                                         • plasma levels of some drugs                                                           • free drug levels of amiodarone,
                                       • α1-acid glycoprotein                                                                                                                                                     diltiazem, dronedarone,
                                                                                                                                                                                                                  propafenone, quinidine, verapamil
  Biotransformation                    • ↓ liver mass and hepatic blood flow • exposure of drugs highly biotransformed                                                                                     • amiodarone, diltiazem, flecainide,
                                              (20-30%)                                                                                                                                                            lidocaine, mexiletine, propafenone,
                                       • ↓ CYP450-mediated phase I                                                                                                                                                propranolol, quinidine, verapamil
                                              reactions
  Excretion                            • ↓ renal mass                        • exposure and half-life of renally-cleared                                                                                   • exposure to ACEIs, renal eliminated
                                       • ↓ renal blood flow, GFR and tubular   drugs                                                                                                                              AT1 antagonists, amiodarone,
                                              function                                                                                                                                                            atenolol—beta adrenolytics, digoxin,
                                                                                                                                                                                                                  nadolol, quinidine, sotalol
  Pharmacodynamic changes
  ...........................................................................................................................................
  Change                                                                                                           Consequence
  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
  Baroreceptor is blunted                                                                                          Postural hypotension, falls: Class I and IV AADs
  Decreased response to catecholamines                                                                             Increased sensitivity to amiodarone, β-blockers and sotalol
  Increased myocardial fibrosis                                                                                    Decreased conduction velocity (Class I AADs)
  Sinoatrial and atrioventricular node dysfunction                                                                 Higher risk of bradycardia and atrioventricular block with Class II and IV AADs and digoxin
  Decreased cardiac reserve                                                                                        Higher risk of HF with disopyramide and Class IV AADs
  Decreased left ventricular compliance                                                                            Decreased cardiac output with Class II AADs
  Increased sensitivity to anticoagulants                                                                          Higher risk of bleeding
  Comorbidities and polypharmacy                                                                                   Increased drug–drug and drug–disease, drug–diet supplements interactions
                                                                                                                   • HF decreases hepatic and renal clearance
                                                                                                                   • Class II AADs, sotalol and propafenone can exacerbate bronchospasm
                                                                                                                   • QT-prolonging drugs increase the risk of torsades—drug interactions
 AADs, antiarrhythmic drugs; ACEIs, angiotensin converting enzyme inhibitors; GFR, glomerular filtration rate; HF, heart failure; Vd, volume of distribution.




CYP1A2 and CYP3A4 isoenzymes (lidocaine).53–57 Age reduces hep­                                                                                  metabolites with electrophysiological effects that can be different
atic blood flow and CYP450 activity increasing the plasma levels and                                                                             from those of the parent compound (N-acetyl-procainamide is a
half-lives of AADs metabolized by the liver.54–58 Biotransformation of                                                                           Class III drug; 5-hydroxypropafenone lacks β-adrenergic blocking ef­
some ADDs (amiodarone, disopyramide, lidocaine, mexiletine, pro­                                                                                 fects). Active metabolites explain why the AADs can exert different
cainamide, propafenone, quinidine, verapamil) produces active                                                                                    effects when the drug is administered intravenously or orally.
1258                                                                                                                                  I. Savelieva et al.



   Age-related reduction in renal blood flow, glomerular filtration          Drug-induced bradycardia
rate and tubular secretion decreases the clearance and increases             Patients with frailty are more often prescribed rate-slowing therapy
the half-lives of renally-cleared drugs (digoxin, ibutilide, sotalol, and    such as calcium channel blockers, beta-blockers and antiarrhythmics
dofetilide).59 Other AADs undergo hepatic and renal elimination              for hypertension, HF, and AF. Frail patients have unpredictable
(dofetilide, procainamide, and disopyramide). Thus, dose adjustment          pharmacokinetics due to reduced first-pass metabolism, reduction
needs to be made for AADs that are directly excreted or whose ac­            in muscle mass and worsening renal function leading to adverse ef­
tive metabolites are eliminated by the kidney. Most AADs interact            fects at standard doses. Even medications within the same class




                                                                                                                                                            Downloaded from https://academic.oup.com/europace/article/25/4/1249/7036349 by Uniwersytet Jagiellonsky w Krakowie user on 05 August 2024
with other widely used drugs. Quinidine, amiodarone, and dronedar­           may differ. In the CIBIS Elderly study, patients with HF randomized
one inhibit the P-glycoprotein required for renal excretion of di­           to bisoprolol or carvedilol had similar incidence of side effects (24–
goxin, thereby increasing its plasma levels. Amiodarone inhibits             25%). However, bisoprolol conferred greater reduction in heart
CYP3A4, CYP2C9, and P-glycoprotein, increasing the plasma levels             rate and more dose-limiting bradycardia (bisoprolol 16% vs. carvedi­
of drugs widely used in the geriatric population (flecainide, Class II       lol 11%), whereas carvedilol was associated with shortness of breath
and IV AADs, anticoagulants).60                                              (bisoprolol 4% vs. carvedilol 10%).66
                                                                                It is estimated that only 15% of AV block is truly caused by drugs.
                                                                             Although resolution of AV block has been reported in 41% when
Adverse effects                                                              rate-limiting drugs are discontinued, over half have recurrence of
Frail patients are more susceptible to some adverse effects of AADs,         AV block in the absence of therapy.67 Patients receiving cholinester­
including bradycardia and atrioventricular (AV) block (Class II and IV       ase inhibitors for dementia are more likely to be hospitalized for syn­
AADs or digoxin), intracardiac conduction block (Class I AADs), HF           cope (HR 1.76) or symptomatic bradycardia (HR 1.69) and to
(disopyramide, sotalol, and IV AADs), orthostatic hypotension and            undergo pacemaker implantation (HR 1.49).68
falls and urinary retention (Class I A).53,61,62 Conversely, older pa­
tients present a decreased sensitivity to beta-blockers. The Beers cri­      Intraventricular conduction
teria recommend to avoid: (i) amiodarone as first-line therapy for AF
unless the patient has HF or substantial left ventricular hypertrophy;
                                                                             abnormalities
                                                                             The incidence and prevalence of bundle branch block (BBB) in­
(ii) disopyramide because of its anticholinergic properties; and (iii) di­
                                                                             creases with age. For 855 men aged 50 years, prevalence of BBB
goxin as first-line therapy for AF or HF and should be prescribed at
                                                                             increased from 1% to 17% over 30 years.69 Isolated right BBB is
doses <0.125 mg/day for any indication.62
                                                                             more frequent than left BBB (0.18% vs. 0.1%), increasing with
    Furthermore, AAD treatment is complicated by coexisting co­
                                                                             age from 0.4% for 45–54 years to 1.3% for >64 years.70 Gender
morbidities (HF, hypertension, coronary artery disease) that affect
                                                                             differences are present; BBB has been observed in 11% of men
the pharmacodynamic/pharmacokinetics of AADs and lead to poly­
                                                                             but only 5% of women older than 60 years.71 In old and frail pa­
pharmacy that increases the incidence of adverse effects and drug in­
                                                                             tients with syncope and bi-fascicular block, empirical pacemaker
teractions. Interestingly, several non-cardiovascular QT-prolonging
                                                                             implantation can be carried out without the preceding electro­
drugs prescribed in the elderly increases the risk of proarrhythmia
                                                                             physiological study.72
and should be avoided.
    Prescribers should carefully evaluate how age affects the pharma­
codynamic/pharmacokinetics of AADs and their possible drug inter­            Pacing: indications, mode selection,
actions with other drugs widely prescribed in older patients with            programming, follow-up, remote
coexisting comorbidities. Treatment should be started at
lower-than-recommended dosages based on hepatic and renal func­
                                                                             monitoring
                                                                             Existing guidelines do not recommend pacemaker therapy be altered
tion and gradually titrated until reaching the desired dose, assessing
                                                                             for the frail patient, other than to consider frailty when considering
for adverse reactions, mainly proarrhythmic effects.
                                                                             cardiac resynchronisation therapy (CRT) and to suggest CRT-pace­
                                                                             maker (CRT-P) over CRT-defibrillator (CRT-D), but stress the need
                                                                             for a thorough review of the individual risk-benefit ratio, including the
Bradyarrhythmias                                                             implications of living with a device, and patient preferences.72,73 The
                                                                             diagnosis of significant frailty along with other risk factors such as ad­
Bradyarrhythmia incidence is known to increase with age and comorbid­        vanced age, limited mobility, and life expectancy-limiting co-morbid­
ity.63–65 Therefore, with increasing frailty, more bradyarrhythmias are      ities may favour the decision to implant a single-chamber
expected. In a murine model, some animals the same age have re­              pacemaker.73 Untreated SND appears to confer a worse prognosis
duced heart rate and sinus node function that can be predicted by            in the frail. With 17-month follow-up, 57% of patients developed
FI. Furthermore, electrical conduction, action potential morphology          syncope, HF, or AF. Multivariate analysis revealed that age of >65
and fibrosis are correlated with, and graded by, frailty scores.63           years was the most important predictor of an event (HR 7.80).74
Idiopathic degeneration of the sinus node caused by ageing is prob­          Generally, the risks of pacemaker implantation are similar in younger
ably the most common cause of SND.64 AV block is more prevalent              and older patients, but pneumothorax, lead dislodgement, and ero­
with advanced ageing. Comparing centenarians with a control group            sion due to low body weight are more common in the elderly.75
averaging 75 years, first- or second-degree AV block was observed            Therefore, given potentially greater benefits of pacing the frail, it is
in 25% of the centenarians compared with 7% of the controls.65               suggested that standard pacing indications are followed, even if taking
Expert consensus document on the management of arrhythmias in frailty syndrome                                                                   1259


into consideration the increased complication risk and costs of the          up to 25% of patients are paced in VVIR mode, which is particularly
procedures.72,73                                                             suitable in the older and frail patients, likely to undergo few device
   Mode selection depends on the indication for pacing. The                  replacements.
UK-PACE trial randomized 2021 patients aged >70 years with high-
grade AV block to single- or dual-chamber pacemaker and found no                Consensus statements
difference in mortality or cardiovascular events.76 In very old and/or
frail patients with infrequent pauses who have limited functional cap­         • Frailty is common in patients with bradyarrhythmias and




                                                                                                                                                           Downloaded from https://academic.oup.com/europace/article/25/4/1249/7036349 by Uniwersytet Jagiellonsky w Krakowie user on 05 August 2024
acity and/or a short expected survival, the benefit of DDD(R) vs.                  usually should not constitute a contraindication to implant
VVIR pacing is expected to have limited or no clinical impact, and                 of a pacemaker.
the incremental risk of complications related to the second atrial
lead should also be taken into account when choosing the pacing
                                                                               • Frailty assessment is required in patients with subtle
                                                                                   deficits as it may determine pacing mode selection and
mode.72 Conversely, maintaining AV synchrony in patients with                      follow-up.
SND reduces AF, pacemaker syndrome and HF hospitalizations.77,78
Patients with suspected deficits should be formally assessed for frailty
using the approved methodology prior to pacemaker implant and se­
lecting the mode of pacing.
   For frail patients, attending follow-up may be arduous. With the          Ventricular arrhythmias
advent of remote monitoring, in-person follow-ups can be minimized
without compromising quality of care. In fact, there is evidence to
                                                                             Ventricular premature beats and
show remote monitoring can be advantageous.79                                ventricular tachycardia
                                                                             The incidence of ventricular arrhythmias increases with ageing inde­
Pacing for undocumented bradycardia                                          pendently of the presence of underlying heart disease,83 and the preva­
Falls are one of the common features of frailty syndrome. Older pa­          lence of ventricular premature beats (VPB) on Holter ECG in older
tients are likely to have multi-factorial aetiology for falls where it may   individuals people has been reported to be as high as 70–80%.84,85
be difficult to differentiate between mechanical falls and falls due to      Frequent VPBs may occur as a result underlying electrical, structural,
other causes, e.g. bradyarrhythmic. The differential diagnosis may of­       ischaemic abnormalities, with different underlying mechanisms such
ten be hampered by cognitive impairment and amnesia. In this set­            as re-entry involving post-MI scarring, enhanced automaticity in the
ting, conventional syncope work-up followed by an implantable                chronically ischaemic tissue, or triggered activity due to afterdepolariza­
loop recorder (ILR) rather than empiric pacemaker implant, is                tions associated with acquired QT interval prolongation or caused by
endorsed.73                                                                  digoxin and are associated with increased risk of developing new-onset
Leadless pacing                                                              cardiomyopathy or worsening of the existing disease.85,86
Leadless pacemakers may prevent some of the complications related               Some monomorphic VPBs, most commonly of the right or left
to implantation including pre-pectoral haematomas, extrusions,               ventricular outflow tract origin occur in the absence of structural
pocket infections, pneumothorax, tamponade and lead dislodge­                heart disease, are not associated with an adverse prognosis and usu­
ment. Vascular complications because of the large introducer sheaths         ally do not require any specific AAD therapy.86
and pericardial tamponade (around 1%) are significant risks in the              Management of frail patients with frequent VPBs on the back­
older frail patients and need to be considered before implanting a           ground of cardiac pathology, chiefly coronary artery and ischemic
leadless pacemaker.80                                                        heart disease or cardiomyopathy is challenging because of the un­
   Over the long-term, the cardiac pacing lead is generally considered       favourable risk/benefit ratio of AAD therapy and only limited data
the system’s weakest link, with risk of the breakdown of the insula­         on VPB ablation in this population. Bundle branch re-entry is rare
tion or wire rupture and infections. The rates of these complications        but needs to be identified since it is curable by ablation.
are increased in the presence of concomitant disorders often asso­              Sudden cardiac death (SCD) in older patients may often be related
ciated with older age. The absence of a lead decreases the rate of           to malignant ventricular arrhythmias.87 The leading cause is myocar­
lead-related complications and the system is compatible with mag­            dial ischaemia, and the prognosis is poor in older patients, with the
netic resonance imaging. These features make leadless pacing an at­          survival rate <5%.88 SCD in old or frail people may also be related
tractive option for older and frail patients in need of a                    to electromechanical dissociation or asystole,87,88 which was asso­
pacemaker.81,82                                                              ciated with a nearly 100% mortality rate in most studies. Older sur­
   Compared to patients with transvenous pacemakers, patients                vivors may often exhibit cognitive or mood disorders highlighting the
with leadless pacing may experience fewer complications but more             influence of age following resuscitated cardiac arrest.89
dramatic pericardial effusions which highlights the care needed for
implantation in older and frail patients. The Micra™ device may
have a safety profile similar to that of a transvenous system while          Pharmacological management of VPBs
providing low and stable pacing thresholds.81                                and ventricular tachycardia
   The long-term status of these devices is unknown, particularly the        The acute management of ventricular tachycardia (VT) includes
risk of endothelialization and fibrosis, which might hamper their ex­        intravenous beta-blockers, amiodarone (150–300 mg iv bolus), lido­
traction. This may need the abandonment of the leadless electrode,           caine, and mexiletine which may also prevent immediate recurrence
which may be a less significant matter for older patients. Currently,        of VT and the occurrence of ventricular fibrillation (VF). Amiodarone
1260                                                                                                                             I. Savelieva et al.



remains the only AAD that could be used in critically ill patients with   action was maintained in the presence of mild left ventricular dys­
frailty.                                                                  function and was sustained in the long-term (∼2–6 years).91

Beta-blockers and non-dihydropyridine calcium                             Amiodarone
antagonists                                                               When beta-blockers alone are ineffective, current evidence suggests
As mentioned earlier, beta-blockers are often considered first-line       that amiodarone is usually beneficial in patients with HFrEF and high
treatment in symptomatic patients with a high burden of ventricular       VPB burden, also considering its cardiac safety. There are different




                                                                                                                                                       Downloaded from https://academic.oup.com/europace/article/25/4/1249/7036349 by Uniwersytet Jagiellonsky w Krakowie user on 05 August 2024
ectopy, but their efficacy is modest. In some cases, a non-               loading regimens of the drug.
dihydropyridine calcium antagonist (verapamil) may be used in se­
lected patients and verapamil-sensitive ventricular ectopy. The same      Other antiarrhythmic drugs
therapeutical principles apply to non-sustained ventricular tachycardia   Based on current evidence, Class IA (disopyramide) and IC (flecai­
(NSVT). Patients with frequent idiopathic runs of NSVT should be          nide and propafenone) agents, despite the efficacy and the wide
evaluated for the primary genetical electrical heart disease.             use of the latter in subjects without significant structural heart dis­
                                                                          ease, are not indicated in patients with underlying cardiac condi­
Mexiletine and lidocaine
                                                                          tions and/or HF which are common in frail individuals, because
Mexiletine and lidocaine are effective in suppression of ectopic ven­
                                                                          of their negative inotropic effect and risk of ventricular proar­
tricular automaticity and triggered activity caused by delayed afterde­
                                                                          rhythmias.58 Pure Class III dofetilide is not available worldwide, in­
polarizations, and they also may interfere with the re-entrant
                                                                          cluding many European countries, whereas the use of a
mechanism of arrhythmias by converting unidirectional to bidirec­
                                                                          multichannel ion blocker dronedarone is limited to AF and is not
tional block in partially depolarized myocardium observed during is­
                                                                          widely used in Europe.
chaemia. The efficacy of mexiletine as monotherapy was assessed in
small studies and during programmed electrical stimulation and ran­       When to intervene?
ged between 20–30% in suppressing induced ventricular tachycardia         There is no established clear cut-off point for the initiation of treat­
and 75% in reducing the number of NSVT runs.90 Mexiletine and             ment with regard to the number of VPBs. Patients with extremely
lidocaine are similar in both structure and function; unlike lidocaine,   frequent VPB (>10% of the total beats during 24-h monitoring)
mexiletine is well absorbed from the gastrointestinal tract.              are deemed more likely to experience some degree of left ventricular
Mexiletine and lidocaine exert an antiarrhythmic effect without sig­      dysfunction or developing arrhythmia-induced cardiomyopathy.92,93
nificant inhibition of cardiac function.                                  A VPB burden of >24% or >20 000 VPBs during the 24-h period has
   Proarrhythmia or other serious toxicity from the drugs is uncom­       shown a strong association with the development of cardiomyop­
mon. Sinus bradycardia and sinus arrest have been documented in           athy.94 However, the threshold varies greatly and may be significantly
patients with pre-existing SND which required monitoring in older         lower in patients with impaired left ventricular systolic function and
frail individuals with a likely impaired sinus and/or AV nodes.           HF, with cardiomyopathy and worsening HF being reported in asso­
   Mexiletine and lidocaine are predominantly metabolized by the li­      ciation with VPB frequency as little as 4%.
ver, and the drug elimination may be delayed in HF and other causes          Other VPB features such as QRS duration as a measure of ven­
of hepatic insufficiency. For treatment of significant ventricular ar­    tricular dyssynchrony, prematurity index, multiform VPBs, increased
rhythmias, mexiletine is given at 200–300 mg tds.; a loading dose         VBP density during exercise, repetitive forms such as ventricular cou­
of 400 mg can be used followed by 200 mg tds., but the maximum            plets and triplets, intrapolated VBPs, VPBs of epicardial origin, and
dose should not exceed 1200 mg/day. The elimination half-life of          duration of exposure to frequent VPBs may be associated with the
mexiletine is 9–12 h.                                                     development of cardiomyopathy or worsening HF and should
                                                                          prompt further imaging such as cardiac MRI and more intensive
D, L-Sotalol
                                                                          follow-up aimed at assessing the frequency of VPBs and left ventricu­
Class III (HERG channel-mediated rapid potassium current block­
                                                                          lar systolic function (an echocardiogram if MRI did not reveal any
ers) D, L-sotalol is generally avoided in frail patients with multiple
                                                                          underlying condition).
comorbidities, polypharmacy, and frequent electrolytes disor­
ders, but may be used in selected patients, more commonly for
ventricular arrhythmias, if certain provision is followed such as         Drug-induced ventricular arrhythmias
QT interval monitoring and ensuing there is no significant left ven­      Acquired long QT potentially resulting in polymorphic and torsade
tricular hypertrophy. Sotalol also exerts a nonselective competi­         de pointes VT is the most significant drug-induced proarrhythmia.
tive beta-1-adrenoceptor antagonism (predominantly confined               The majority of AADs may cause proarrhythmia, particularly in the
to the levo-isomer, I-sotalol).56 It is effective in suppressing com­     presence of precipitating factors such as electrolyte abnormalities
plex forms of ventricular ectopy, displaying superior anti-ectopic        and drug interaction,56 with torsade de pointes considered a sig­
activity to beta-blockers in patients with stable coronary artery         nificant concern in frail patients where electrolyte disorders and
disease, but is not suitable for patients with HF on the background       polypharmacy are common. The main cause is iatrogenic QT pro­
of hypertensive heart disease and left ventricular hypertrophy and        longation (the full list of agents with a torsadogenic potential may
significant left ventricular systolic impairment. Sotalol 160–            be seen at https://crediblemeds.org), but it may also occur when
640 mg/day reduced ventricular ectopy, most notably higher                QT prolongation is secondary to sinus bradycardia or AV block.
grade ventricular arrhythmias (polymorphic and repetitive prema­          Thus, in the study of 202 hospitalized patients aged above 75 years,
ture ventricular complexes, couplets and runs of NSVT); this              22% of VT cases were ischaemic and 50% were iatrogenic.84
Expert consensus document on the management of arrhythmias in frailty syndrome                                                                   1261


Treating proarrhythmias                                                     Knowledge gaps
Effective treatment requires the accurate recognition and confirm­
ation of drug-induced proarrhythmia and prompt discontinuation              • Due to multi-morbidity and polypharmacy, the usual risk assessment
                                                                                for proarrhythmias may not be sensitive in patients with frailty syn­
of the implicated agent. Important are also the identification
                                                                                drome; a standardized protocol specifically developed for frail pa­
modification of risk factors potentially associated with arrhythmia
                                                                                tients may be required.
onset or worsening (e.g. female gender, advanced age, renal or liver
dysfunction, underlying structural heart disease, hypokalaemia, hypo­
                                                                            •   There is very limited data on the efficacy and safety of ablation for
                                                                                ventricular arrhythmias in frail patients; an international registry is




                                                                                                                                                          Downloaded from https://academic.oup.com/europace/article/25/4/1249/7036349 by Uniwersytet Jagiellonsky w Krakowie user on 05 August 2024
magnesaemia, high drug doses/concentrations, rapid intravenous ad­              needed to accumulate these data in a structured fashion.
ministration, bradycardia, QT prolongation, and pre-existing
channelopathies).56
   The offending drug should be stopped, and intravenous adminis­               Consensus statements
tration of magnesium sulfate irrespective of serum magnesium levels
should be administered (e.g. 2000 mg bolus followed by a second bo­             • If patients are symptomatic with VPBs and/or develop
                                                                                   evidence of worsening left ventricular systolic function,
lus and by continuous infusion if the proarrhythmia persists).
                                                                                   appropriate therapy should be commenced immediately
Bradycardia and pauses that may trigger torsade de pointes should
be reversed by either pacing at >70 bpm or isoproterenol infusion.              • Patients with very frequent VPBs (>20% per 24 hours) at
Hypokalaemia should be corrected, aiming at replenishing serum po­                 increased risk of developing cardiomyopathy should
tassium to the high-normal range (i.e. 4.5–5.0 mEq/L).                             immediately commence appropriate therapy in order to
   Beta-blockers may be used in some circumstances. In milder                      improve prognosis and prevent the occurrence of
cases, arrhythmias due to digitalis toxicity can be managed by discon­             cardiomyopathy
tinuation of the drug, potassium supplementation and observation.               • Patients with newly diagnosed frequent VPBs (>500 per
For digitalis-induced life-threatening arrhythmias, several AADs                   24 h) should be referred for specialist assessment
have been proposed in the past (e.g. phenytoin, lidocaine and beta-                including cardiac imaging (echocardiography, cardiac MRI,
blockade). More recently, digitalis-specific antibodies have proven ef­            exercise stress test, etc.), even asymptomatic, in order to
fective in reversing digitalis toxicity by rapidly binding to and acutely          exclude any underlying electrical and/or structural
lowering serum digitalis. Isoproterenol infusion or cardiac pacing are             abnormality of the heart
usually effective when symptomatic bradyarrhythmias secondary to                • In parallel with specialist electrophysiologic investigation
conduction abnormalities occur.                                                    and prior to the initiation of therapy, patients should be
                                                                                   carefully assessed for the presence of a frail status; even
                                                                                   subtle deficits should be identified and corrected,
Ablation for ventricular arrhythmias                                               preferably prior to intervention
In patients with high VPB burden and arrhythmia-induced cardio­                 • Optimal medical therapy should also aim at underlying
myopathy worsening HF, ablation may be a preferred treatment                       heart disease
option which has been reported to result in a sustained reduction               • Ablation of frequent VPBs which cause left ventricular
in the VPB burden and associated with a lower risk of hospitaliza­                 systolic dysfunction may be offered to selected patients,
tion for HF, cardiac death, or the need for heart transplant.95                    after thorough assessment of the risk–benefit ratio of this
However, this intervention has not been explored in prospective                    intervention; many patients with frailty syndrome are
studies and is limited in patients with frailty syndrome. Some                     unlikely to be candidates for ablation
data available from the retrospective cohorts enrolling older pa­
tients ≥70 years with structural heart disease (but without system­
atic formal frailty assessment) undergoing ablation for VT suggest
that older individuals were more likely to sustain peri- procedural         ICD: indications, selection, and outcome
complications and had higher in-hospital (4.4% vs. 2.3%; P = 0.01)          Implantable cardioverter-defibrillator (ICD) therapy is beneficial in
and 1-year mortality (15% vs. 11%; P = 0.002) compared with their           older patients for primary prevention of SCD when life expectancy
younger counterparts, but a similar incidence of VT recurrence at           is >1 year.97,98 Randomized studies have reported divergent results
1 year (26% vs. 25%) and time to VT recurrence (280 vs. 289                 on the benefit of ICDs in older patients.99,100 In well-selected patients
days).96 The absence of VT recurrence during follow-up was                  at high risk of arrhythmic death and with few comorbidity factors des­
strongly associated with improved survival in patients ≥70 years.           pite advanced age, ICD intervention may reduce mortality to nearly
It should be acknowledged that these data concern older, but                age-specific life expectancy. It should be acknowledged that these
not necessarily frail individuals and that these data cannot be extra­      were highly selected populations, and the indications for a primary pre­
polated on patients with frailty. On the other hand, these patients         vention ICD in the non-ischaemic population is not strong enough to
may potentially derive a great benefit from the procedure as it may         warrant routine ICD implantation in the older and frail patients because
eliminate the long-term risk of pharmacological rhythm control.             of the competing causes for deaths (usually non-cardiac). Thus, in the
While it would be challenging to carry out a prospective trial in           recent study of octogenarian primary prevention ICD recipients, three
this setting, collecting data on VT ablation in frail patients should       quarters had no more than one comorbidity, resulting in similar rates of
constitute part of national ablation registries or an international         both appropriate and inappropriate device therapies compared with
registry should be initiated.                                               their younger counterparts.99 Among patients who died during
1262                                                                                                                                 I. Savelieva et al.



19-month follow-up (35%; of these 38% from non-cardiovascular               from 77 to 98 437 and follow-up ranging from days to 6 years, has
causes), one-third received at least one appropriate ICD therapy.           revealed that patients with elements of frailty defined according to
   In a cohort of 83 792 Medicare patients the NCDR ICD registry,           varying validated methods, including cumulative deficit models, low
who underwent first primary prevention ICD implantation, approxi­           weight, and walking speed, had higher all-cause or peri-operative in-
mately 1% had dementia, whereas 10% had frailty defined using a             hospital mortality.107 As mentioned earlier, there is no uniformly es­
coding algorithm of frailty markers based on 99 ICD-9 codes, se­            tablished score to assist in identification of a suitable candidate for
lected by a group of geriatricians, and categorized into 10 clusters:       ICD therapy in frailty, although some physical components, such as




                                                                                                                                                           Downloaded from https://academic.oup.com/europace/article/25/4/1249/7036349 by Uniwersytet Jagiellonsky w Krakowie user on 05 August 2024
malnutrition, dementia, severe vision impairment, decubitus ulcer,          a 6-minute walking test, timed chair stands and balance, handgrip
incontinence of urine, incontinence of faeces, weight loss, social          strength, as well as questions about weight loss, physical activity,
support needs, difficulty walking, and falls.100 Patients with demen­       and exhaustion, have been found useful in some reports.107,108
tia and frailty had substantially higher mortality within the first year       Wearable cardioverter-defibrillators may be an alternative to
after ICD implantation (27% and 22%, respectively) compared                 some patients. However, these devices require a high level of com­
with those without these conditions (12%). Several multi-                   pliance, good understanding how it works, and a certain physical
morbidity patterns were associated with high 1-year mortality               strength. Therefore, these devices will have a limited role for preven­
rates: dementia with frailty (29%), frailty with COPD (25%), and            tion of SCD in frail patients.
frailty with diabetes (23%).
   The predictive usefulness of Charlson Comorbidity Index (CCI)            ICD programming in frail older patients
has recently been explored in older (mean age: 78 years) candidates         Recent ICD studies focused on new programming strategies in pa­
for ICD.101 At 5-year follow-up after ICD implantation, survival            tients with little or no exclusion criteria in order to decrease the
was 78%, 57%, and 29% in patients with a CCI score of 0–1, 2–3,             rate of inappropriate therapies and to deliver less aggressive therapy
and ≥4, respectively, compared with 72% in non-frail controls.              in case of sustained ventricular arrhythmia.109–113 Whether such
There was no significant difference in appropriate ICD therapy.             modern strategies are as safe and efficient in elderly patients is an
The median potential survival gain after an appropriate therapy             open question, but such conclusions can be made from these studies.
was >5, 4.7, and 1.4 years, with a CCI score of 0–1, 2–3 and ≥4, re­        Prolonged detection as well as high VF rate settings decrease the
spectively. The limitations of CCI include difficulties using in clinical   number of inappropriate therapies and the number of shocks with
practice, not being developed in older adults, whereas conditions           the use of antitachycardia pacing in fast VT. Such programming para­
that may have the most bearing on outcomes, such as frailty and de­         meters are proposed in current consensus documents by scientific
mentia, are not incorporated or not appropriately weighted.                 societies112,113 and may be safely applied in elderly or frail patients.
   Therefore, a multivariable score (rather than chronological age per
se) and individualized consideration, focusing on comorbidities, pro­       Subcutaneous ICDs
jected expectancy, the life-long risk of complications, impact of an        The subcutaneous ICD (S-ICD) is emerging as a therapy for the pre­
ICD on quality of life, including psychological health, and patient pref­
                                                                            vention of SCD avoiding the complications associated with transve­
erence should help in decision-making for ICD selection and its sur­        nous leads.114 The S-ICD system is essentially promising in terms of
vival benefit.102                                                           reduction of electrode-related complications such as infection or
   In secondary prevention ICD, a meta-analysis suggested that ICD
                                                                            lead failure, which may be more relevant for relatively young and ac­
therapy did not show any survival benefit in patients aged >75 years        tive patients. This may, however, be an option in elderly or frail pa­
[HR for all-cause death 1.06 (95% CI: 0.69–1.64), HR for arrhythmic         tients in case of limited vascular access or persistent infection. Low
death 0.90 (95% CI: 0.42–1.95)].103 However, older age does not di­
                                                                            body weight at baseline and risk of progressive body mass and muscle
minish the likelihood of receiving appropriate therapy.104 A careful        loss, unless revised and corrected, may be the limitation for implant­
evaluation of comorbidities that may increase the relative risk of non-     ing S-ICD in patients with higher frailty scores.
arrhythmic mortality is again needed.
   In the oldest patients, discussion regarding the effect of implanta­
ble devices on the mode of death (ICD preventing SCD but exposing
                                                                            Lead failure management
                                                                            The need for managing CIED infection and abandoned leads in­
to the risk of prolonged and progressive HF) takes a particular place
                                                                            creases with advanced age. There are numerous gaps in evidence re­
in decision-making according to patient choice.105,106 ICD interven­
                                                                            garding lead extraction tools, management of abandoned and
tion among the elderly as a group may be less cost-effective, but cost-
                                                                            recalled leads, prevention and treatment of infections, and risk strati­
effectiveness is expected when ICD is implanted in patients expected
                                                                            fication for lead extraction. Such evidence in older and frail patients is
to live sufficiently, e.g. >5–7 years after implantation.106
                                                                            difficult to collect because the number of such patients even in high-
   However, in all these studies much of information comes from
                                                                            volume centres, is too low to create statistically solid data. In very old
carefully selected older individuals with few comorbidities, low-grade
                                                                            and frail patients with limited life expectancy, leads (and the gener­
frailty, or from mixed populations using heterogeneous definitions
                                                                            ator, if therapy is terminated) are usually abandoned.
for frailty, as this was not the primary endpoint in these studies.
The presence of frailty generally was an exclusion criterion from
both RCTs and even observational studies. Hence, very limited               Knowledge gaps
data exist regarding the risk–benefit of ICD therapy. A review of
nine studies, including two RCTs, one prospective cohort, and six
                                                                            • The decision on implantation of an ICD or CRT-D in a patient with
                                                                               frailty should be assisted by a dedicated simple and robust score in
retrospective cohort studies, with the number of patients ranging              order to ensure equal access to therapy for all frail patients; such a
Expert consensus document on the management of arrhythmias in frailty syndrome                                                                     1263


   score should be developed to be specifically used in people with         than in non-frail individuals, with the majority of deaths occurring
   frailty.                                                                 from HF rather than arrhythmic causes. This underscores the need
                                                                            for systematic screening for frailty in patients at risk who have
   Consensus statements                                                     been offered CRT and the importance of optimal medical therapy
                                                                            and exercise training to reverse or deter frailty-related reduced mo­
  • In selected patients at high risk of arrhythmic death and               bility and nutritional and cognitive impairment.
      with few comorbidity factors despite advanced age,




                                                                                                                                                           Downloaded from https://academic.oup.com/europace/article/25/4/1249/7036349 by Uniwersytet Jagiellonsky w Krakowie user on 05 August 2024
      primary ICD prevention may reduce mortality.
                                                                            Knowledge gaps
  • Device programming to deliver optimal ICD therapy
      aimed at fewer shocks for sustained ventricular                       • Difficulty assessing frailty in the presence of HF due to the overlap of
      arrhythmia may be applied in older frail patients.                      two conditions, suboptimal performance of frailty assessment tools.
                                                                            • No reliable tools for the prediction of life expectancy in patients with
                                                                                HF and frailty which is essential for the selection of appropriate ther­
                                                                                apies (e.g. CRT-D, ICD).
Heart failure and cardiac                                                   •   Lack of data on the outcome of therapies due to the exclusion of eld­
                                                                                erly frail patients and patients with multiple comorbidities from clin­
resynchronization therapy                                                       ical trials—studies should include the full spectrum of
                                                                                community-dwelling and institutionalized older adults and assess
Definition and assessment of frailty in HF                                      such measures as health status, quality of life, functional capacity, as
Among all cardiovascular pathologies, HF has the strongest link with            well as conventional outcomes.
frailty, with up to 79% of patients with HF identified as frail.3,23 The    •   Further research is needed focusing on the link between mental
two conditions share several pathophysiological mechanisms, pri­                health (depression) and the clinical course and outcome of HF in as­
marily myocardial and metabolic incompetence, implicated in a so-               sociation with frailty.
called ‘dependency cascade’—a process that identifies a sequence            •   Need for the improved awareness of frailty and structured manage­
of progressive damage involving multiple organ systems that perpe­              ment with an emphasis on symptom control, exercise training, and
tuates itself. 115,116 The rates of mortality and hospitalization are the       quality of life via rehabilitation programmes.
highest in patients with HF who are also identified as frail.
                                                                                Consensus statements
   Assessment of frailty is essential in the management of older pa­
tients with HF as chronological age does not automatically identifies
the health status. Heart Failure Association (HFA) has proposed a
                                                                                • Targeted rehabilitation programmes focusing on strength,
                                                                                   balance, and gait training may be beneficial in deferring the
definition of frailty in patients with HF as a multidimensional dynamic            progression of frailty and may partially reverse
and partially reversible state, independent of age, that makes the in­             frailty-associated symptoms and improve quality of life.
dividual with HF more vulnerable to the effect of stressors.3
Although several frailty assessment instruments have been used in
                                                                                • In patients selected or treated with CRT/CRT-D,
                                                                                   screening for frailty may be useful in order to assess CRT
HF patients,117 none of them has been validated in HF. HFA has                     outcome and the effects of timely applied measures to
called for the development of a score that is disease-specific to iden­            counteract mobility, nutrition, and cognitive function
tify frailty in HF.                                                                deficits.


CRT: indications, optimization, follow-up
CRT with (CRT-D) or without defibrillator function is one of the
most widely employed non-pharmacological managements of pa­
                                                                            Device replacement, upgrade/
tients with NYHA II–IV class HF, wide QRS complex (primarily                downgrade, and deactivation at
LBBB), and left ventricular ejection fraction <35%, with proven effi­       end of life
cacy in symptom relief, improvement in exercise capacity and quality
of life, hospitalization for HF, and mortality.72,118 The prevalence of     Patients with cardiovascular disease at risk of arrhythmic death
frailty in patients treated with CRT has not been systematically as­        and/or heart failure are candidates for ICD and/or CRT, yet, pa­
sessed, but several small studies, using various frailty measurement        tients with cardiovascular disease are likely to become frail.23,122
tools, have reported that it may be as high as 81% in patients under­       Clinical effectiveness of ICDs in older populations may be due to
going de novo implant and 68% in those undergoing the system                “healthy candidate” bias.123 Frail patients, being at great risk of
upgrade.119                                                                 death and disability are less desirable candidates for CRT upgrade,
   The benefits of CRT in frail patients are expected to be lower due       ICD implant and/or replacement106,124 and many become frail
to multiple comorbidities, including the higher prevalence of AF, al­       after ICD implant, at time of pulse generator change. A median
though preliminary reports have suggested that the progression in           of 1.2 life-years were gained for those > 80 who came for ICD re­
frailty-associated symptoms, such as cognitive impairment, can be           placement (2-year mortality 38.1%; 16.7% having life-threatening
deterred by CRT.120                                                         arrhythmias).104 While no prospective trial proves lack of any
   Frailty defined by G8 score <14 was associated with a poorer re­         benefit from ICD replacement or CRT upgrade in a frail popula­
sponse to CRT and a higher proportion of non-responders.119,121             tion, a substantial percent of frail patients are less likely to respond
Mortality and hospitalization rates were also significantly higher          to CRT (53% vs 73%),119 and are at greater risk of heart failure
1264                                                                                                                                     I. Savelieva et al.



decompensation (55.6% vs. 16.4%),125 cardiovascular readmission                  Supraventricular arrhythmias
and death119,126 after device implant. Frail patients also have risk of
complications including infection, erosion, perforation, and, if ne­             Atrial tachycardias are the least frequent form of supraventricular ta­
cessary, lead extraction with poor outcomes.                                     chycardias in the general population, and there are no specific data in
   Before ICD replacement, at end-of-battery life, frailty (an albeit            frail patients. There is a higher proportion of macro-re-entrant atrial
multifaceted, non-dichotomous condition) should be re-assessed                   tachycardias with advance age.83,130 Atrial tachycardia is often
(perhaps in part via activity device monitors127) and, whether or                drug-resistant, whereas ablation may be ineffective due to significant




                                                                                                                                                               Downloaded from https://academic.oup.com/europace/article/25/4/1249/7036349 by Uniwersytet Jagiellonsky w Krakowie user on 05 August 2024
not ‘appropriate’ antitachycardia therapies have been given, it is rea­          atrial remodelling.
sonable to forgo ICD replacement and even consider turning off the                   Atrial flutter rates increase significantly with ageing, ranging from
device.128 For those considered for CRT upgrade, similarly, based on             5/100 000 in patients under 50 years of age to 587/100 000 in those
the severity of the frailty and underlying comorbidities, it is reason­          aged 80 years and older.131 Older frail patients have higher rates of
able to forgo CRT revision.                                                      impaired heart rate response and variability characteristics that are
   Because of potentially lower efficacy and higher risk of complications        further reduced with poor mobility. Although these patients are
of device therapy, particularly ICD and CRT-D in patients with frailty           less likely to be treated with ablation, limited data in selected indivi­
syndrome, an informative and honest discussion involving legal and eth­          duals who were functionally preserved, ablation of typical atrial flut­
ical issues, including the eventual need for device deactivation should be       ter had a high success rate of 86% and was not associated with excess
held with the patient and a caregiver in all individual cases. In frail pa­      complications.132
tients, to improve the dying process, and, with informed, and complete,              Atrioventricular node re-entrant tachycardia can present later in
knowledge of the consequences, it is reasonable for the patient, or legal        life due to an increase in triggers from ageing and coexistent cardio­
representative, to request deactivation of any, and all, ICD or CRT and          vascular diseases. Age-related changes in the AV node electrophysi­
to work with the doctor to ensure this occurs.128                                ology may lead to prolongation of atrial refractoriness of the slow
   However, as generally there is insufficient data, there is also lack of       pathway. No systematic data is available on the efficacy and safety
directives regarding advance care planning including device deactiva­            of AV node modification, some limited series reported success rates
tion, palliative, and end-of-life care, whereas lack of training for             up to 98%.133
healthcare providers (e.g. 90% are willing to discuss withdrawal of
various life support therapies, but less than 50% would engage in
the discussion of ICD deactivation) creates an unmet need in such                Atrial fibrillation
as sensitive matter.
                                                                                 AF is the most prevalent sustained cardiac arrhythmia in adults, asso­
   ICD recipients need education and conversation with their physi­
                                                                                 ciated in a multifaceted manner with significant morbidity and mor­
cians about managing their devices in a systematic fashion. As one
                                                                                 tality, hospitalization and impaired quality of life.134 Hospitalized AF
survey from octa- and nonagenarian Swedish ICD recipients has re­
                                                                                 patients have been shown to have a four-fold greater odds of being
vealed, one-third (34%) had discussed their illness trajectory with
                                                                                 classified as frail in comparison to non-AF patients independently of
their physician, a minority (13%) had discussed what turning off
                                                                                 age, sex and comorbidity.135,136
shocks would involve with their physician, and just 7% had told their
                                                                                    The prevalence of frailty in AF patients ranged from 4.4% to
family their wishes about a possible deactivation in the future. About
                                                                                 75.4%, while AF prevalence in the frail population ranged from
one-fourth of the octo- and nonagenarians had insufficient knowl­
                                                                                 48.2% to 75.4%.137 Among AF patients, frailty was significantly asso­
edge regarding the ethical aspects, function of the ICD, and practical
                                                                                 ciated with prolonged hospitalization and increased symptom sever­
consequences of withdrawing the ICD treatment in the
                                                                                 ity, incidence of stroke and all-cause mortality.136,138
end-of-life.129 However, it is important that the majority of partici­
                                                                                    Owing to a greater prevalence of cognitive impairment, tendency
pants expressed their desire for battery replacement when one
                                                                                 to fall, polypharmacy and cardiovascular or other comorbidity
was needed, even if they had reached a very advanced age (69%),
                                                                                 among frail patients, management of AF in such setting may be chal­
or were seriously ill with a life-threatening disease (55%).
                                                                                 lenging, since anticipated suboptimal adherence to treatment, drug–
                                                                                 drug interactions and increased bleeding risk may influence treat­
Knowledge gaps                                                                   ment decisions. The ABC-integrated AF management pathway139
• Need for developing a plan for the structured and sensitive discussion         (Figure 2), that provides a holistic approach to management of AF pa­
   involving the physician, the frail patient and his/her family about the       tients and reminds clinicians of essential decision-making steps in this
   possibility of a rapid clinical deterioration, with the onset of a terminal   process, also applies to frail AF patients.
   condition and the need for device inactivation and an advance care
   provision.
                                                                                 Rate vs. rhythm control management
   Consensus statement                                                           There are two primary clinical approaches to managing the
                                                                                 arrhythmia.
  • An informative and honest discussion involving legal and                        Rate control: slowing the ventricular rate to a level which is physio­
      ethical issues, including the eventual need for device                     logically appropriate. Advantages of the rate control approach in­
      deactivation should be held between the physician, the                     clude ease simplicity avoiding the potential toxicity of AADs or the
      frail patient, and a caregiver in all individual cases.                    risks and discomfort associated with electrical cardioversion or inva­
                                                                                 sive left atrial ablation for recurrences of AF.
Expert consensus document on the management of arrhythmias in frailty syndrome                                                               1265


   Rhythm control: restoration and long-term maintenance of sinus           effect of amiodarone is an additional benefit, particularly in paroxys­
rhythm; AADs (ion channel blockers) are predominantly used but              mal AF.
occasionally autonomic manipulation, for example with beta-
blockers may prove valuable.                                                Knowledge gaps
   Rate control remains an essential component of therapy even if
the primary strategy is rhythm control (e.g. in the case of a recurrent     • The consequences of the reduction in arrhythmia burden for disabil­
                                                                               ity and frailty development or reversal constitute an important
arrhythmia).




                                                                                                                                                       Downloaded from https://academic.oup.com/europace/article/25/4/1249/7036349 by Uniwersytet Jagiellonsky w Krakowie user on 05 August 2024
                                                                               knowledge gap in geriatric cardiovascular medicine.
   Two targets of rate control have been debated: (i) strict rate con­
trol with a target ventricular rate response of <80 bpm at rest and
<110 bpm on moderate exercise, usually achieved by the combin­              Stroke prevention
ation of two drugs with an AV blocking effect and repeatedly as­            General principles
sessed by different means including an ECG, ambulatory Holter               Optimal prevention of stroke or systemic thromboembolism asso­
ECG monitoring, exercise stress test, and in some circumstances, im­        ciated with AF involves three crucial steps (Figure 2).139
plantable rhythm monitoring devices, and (ii) lenient rate control             Clinician first needs to identify truly low-risk patients (i.e., men
which allows ventricular rates of <110 bpm at rest which usually            with a CHA2DS2-VASc score of 0 and women with a CHA2DS2-
does not require extensive monitoring.134                                   VASc score of 1 due to female sex), who do not need any antithrom­
   While lenient rate control with a resting heart rate <110 bpm can        botic therapy, whereas all other AF patients benefit from a stroke
be employed as the initial target, it should not lead to the assumption     prevention strategy, using oral anticoagulant (OAC) drugs [prefer­
that lenient rate control remains an acceptable, or preferable, option      ably a non-vitamin K antagonist OAC (NOAC), or, alternatively, a
to a more aggressive rate control approach in the long-term. Lenient        well-managed vitamin K antagonist (VKA), with ≥70% time in thera­
rate control, often employing a single agent is suitable for older frail    peutic range (TTR)].134,141 The preference to NOACs over VKAs
individuals with limited morbidity, in whom AF is deemed permanent          largely stems from their better safety, especially concerning haemor­
and is asymptomatic.                                                        rhagic stroke and other intracranial bleeding, and more convenient
   Beta-blockers, which are part of the mainstream therapy of HF, re­       long-term use in comparison to VKAs.142
present the first-line choice for acute and long-term rate control, es­        The concomitant assessment of bleeding risk is needed to control
pecially in patients with evidence of HF (particularly, HFrEF and           modifiable risk factors and to identify patients with non-modifiable
HFmrEF), due to their efficacy at high sympathetic drive. Digoxin           risk factors, who will need frequent clinical follow-up evaluations.
(62.5–250 µg daily), which has an antiadrenergic effect, increases          The use of the well-validated HAS-BLED bleeding score was superior
the AV node refractory period, and inhibits the sodium-potassium            to the approach concerning only modifiable bleeding risk factors in
adenosine triphosphatase pump—with the resultant improvement                multiple cohorts,143–146 likely due to a more holistic bleeding risk
in ventricular contractility—can also be used as a first-line rate con­     management using the HAS-BLED score. Importantly, neither stroke
trol drug in permanent AF patients intolerant to beta-blockers, par­        nor bleeding risk are static, but change over time and need to be re-
ticularly, in older, sedentary, ones. Digoxin is beneficial as a            assessed during clinical follow-up.134,142
second-line remedy in those with a suboptimal response to beta-
or calcium channel blockers. In a small randomized open label study         Antithrombotic management in old and frail
in older patients the majority of whom had HFpEF, digoxin favoured          A meta-analysis of 6 studies suggested that OAC prescribing pat­
better than bisoprolol in respect of symptom relief and quality of life     terns in frail AF patients are influenced by a complex interplay of mul­
scores and was associated with a greater adherence to treatment at          tiple factors including thromboembolic and bleeding risks, frailty
6 months.140 Digitoxin is a potential alternative to digoxin and is cur­    status and AF management setting (e.g., the community, hospital
rently being evaluated in a randomized placebo-controlled trial             or nursing care) reflective of concomitant competing risks, life ex­
(ClinicalTrials.gov Identifier: NCT03783429). As a last resort amio­        pectancy, physician’s expertise in AF management and completeness
darone is advocated, especially in patients with HFrEF.134                  of case assessment.136
   Of the two prime treatment strategies for AF rhythm control is              Factors that may influence OAC under-prescription or discon­
intuitively more attractive as it offers physiological rate control, nor­   tinuation, such as advanced age, multiple comorbidities, impaired
mal atrial activation and contraction, the correct sequence of AV ac­       cognitive function, suboptimal adherence and increased bleeding
tivation, normal haemodynamic and AV valve function, and                    risk,136,146 are commonly seen in the general AF population.
theoretically eliminates one (stasis) or more (endothelial abnormality      Regarding advanced age, warfarin was associated with a positive
or increased thrombogenic blood constituents) of Virchow’s triad of         net clinical benefit in AF patients aged ≥75 years in comparison to
elements that encourage thrombosis within the atria and emboliza­           aspirin [a 2% absolute risk reduction in stroke or systemic embolism,
tion of blood clots to potentially critical parts of the circulation.       with comparable major bleeding rates (1.4% vs. 1.6%)],147 as well as
Elimination of irregular AV conduction, which adds to ventricular           in those ≥90 years old in comparison to no therapy or antiplatelet
dysfunction, is an important component of the beneficial effects of         drugs.148
the rhythm control approach. However, the choice of AADs in frail              All trials of NOAC treatment in AF included significant popula­
patients with multiple comorbidities, polypharmacy, reduced repo­           tions of older people (defined as ≥75 years) ranging from 31% to
larization reserve, and high risk of proarrhythmia is often limited to      43% in the individual trials, comprising over 27 000 older patients
amiodarone. The relative cardiac safety of amiodarone should be ba­         in whom NOACs were studied. In a meta-analysis of pivotal
lanced against significant extra-cardiac side effects. The rate-slowing     NOAC AF trials, overall efficacy and safety of NOACs were
1266                                                                                                                                       I. Savelieva et al.




                                                  The Atrial fibrillation Better Care (ABC) pathway

                                                                             Step 1: Identify low-risk patients.
                                            A      Avoid stroke              Step 2: Offer stroke prevention to patients with
                                                   Optimize stroke           ≥ 1 risk factors for stoke. Assess bleeding risk.
                                                   prevention                Step 3: Decide on OAC (either a VKA with well-
                                                                             managed TTR or a NOAC).




                                                                                                                                                                 Downloaded from https://academic.oup.com/europace/article/25/4/1249/7036349 by Uniwersytet Jagiellonsky w Krakowie user on 05 August 2024
                                                   Better symptom
                                            B      management
                                                                             Patient-centered and symptom-directed
                                                                             decisions on rate versus rhythm control.
                                                   Treat symptoms

                                                                             Manage hypertension, heart failure, diabetes
                                                   Comorbidities/            mellitus, cardiac ischaemia and sleep apnea.
                                            C      risk factors              Lifestyle changes: obesity reduction, regular
                                                   Manage risk factors       exercise and reduction of alcohol/stimulant use.
                                                   and comorbidities         Patient psychological morbidity.
                                                                             Consider patient values and preferences.


  Figure 2 The ABC-integrated AF management pathway. Adapted from Lip GYH.139 ABC, Atrial fibrillation Better Care; AF, atrial fibrillation;
  NOAC, non-vitamin K antagonist oral anticoagulant; OAC, oral anticoagulant; TTR, time in therapeutic range; VKA, vitamin K antagonist.


consistent in all age groups,141 but there was a significant interaction              Additional considerations when choosing OAC drug (and dose)
between age and extracranial major bleeding rates with both dabiga­                for a frail AF patient include low body weight (which is a
tran doses in patients aged ≥80 years (in comparison to warfarin,                  dose-reduction criterion for apixaban and edoxaban), polypharmacy
event rates were similar with the 110 mg dose and significantly higher             (with increased potential for drug–drug interactions) and comorbid­
with the 150 mg dose).149 No such interaction was seen with rivar­                 ity (i.e. CKD, malignancy, epilepsy, etc.) and are discussed in detail in
oxaban,150 apixaban,151 or edoxaban.152 Indeed, the higher absolute                the EHRA Practical Guide on the use of NOACs in AF patients.160
stroke risk in the elderly resulted in a larger absolute risk reduction            Weight is an important factor affecting the dose selection in a frail
with NOACs vs. VKAs and a lower number needed to treat in com­                     patient. Low body weight (usually defined as BMI <18.5 kg/m2)
parison to younger patients.152 Overall, prescribing aspirin instead of            may increase exposure to any NOAC and therefore, may increase
OAC in the elderly with AF was actually harmful—the rates of major                 the risk of bleeding. Body weight ≤ 60 kg requires dose reduction
bleeding with aspirin were similar to those with well-managed                      of apixaban [in patients with age ≥ 80 years and/or serum creatinine
VKAs147 or NOACs,153 whereas aspirin was essentially ineffective                   ≥133 mmol/L (1.5 mg/dL)] as well as for edoxaban, whereas it is in
in stroke prevention.154 Extreme frailty was linked to increased                   itself not a factor for dose reduction of rivaroxaban or use of lower
risk of bleeding associated with aspirin.134                                       dose dabigatran. Noteworthy, prescribing a reduced dose of OAC is
   The use of VKAs was associated with better cognitive function                   less effective in preventing AF adverse outcomes.
in comparison to aspirin among elderly AF patients, and better                        Notwithstanding all these factors, frailty itself should not preclude
cognitive function was also observed among NOAC users com­                         the use of OAC (preferably a NOAC) in eligible AF patients.
pared with warfarin.155 In a meta-analysis of five AF studies (one                 Observational data suggest that among frail AF patients OAC use
RCT, four observational), OAC use was associated with a signifi­                   is associated with lower event rates compared with OAC non-use
cant 21% risk reduction in dementia vs. no antithrombotic ther­                    or aspirin.136 In acutely hospitalized frail elderly AF patients, OAC
apy, and a TTR of ≥75% was associated with less dementia                           non-use was associated with significantly higher adjusted rate of
among warfarin users.156 Pivotal NOAC AF trials have not specif­                   composite outcome of ischaemic stroke or bleeding compared
ically addressed cognitive function, but numerous trials are cur­                  with OAC use [HR 4.54 (95%CI, 1.83–11.25)],138 and in a
rently investigating the effects of NOACs on cognitive function                    community-dwelling cohort of older AF patients using OAC, the
in AF patients.                                                                    stroke incident rate was higher than that of major bleeding (1.73
   Falls are more common among frail AF patients and are a                         vs. 0.9/100 person-years).161 In a retrospective, propensity score-
marker of increased risk of adverse events, but not an independent                 matched analysis of a US administrative dataset of frail AF patients,
predictor of OAC-related bleeding, and the net clinical benefit of                 stroke or systemic embolism rates were significantly lower with riv­
OAC outweighs the risk of severe bleeding among AF patients                        aroxaban vs. warfarin [1.78 vs. 2.61, HR 0.68 (95%CI 0.49–0.95)] and
who sustained falls. Treatment effects of apixaban and edoxaban                    similar with apixaban (1.68 vs. 2.15) and dabigatran (2.06 vs. 2.20) vs.
were consistent irrespective of the falling risk status, with a larger ab­         warfarin, while major bleeding rates were similar with all four OAC
solute risk reduction with the respective NOAC vs warfarin, owing                  drugs and intracranial bleeding was significantly lower with all three
to the greater absolute risk of events among patients at increased risk            NOACs compared with warfarin.162
of falls.157,158 In a propensity score matched analysis of Medicare                   The ELDERCARE-AF trial was a placebo-controlled trial investi­
data, apixaban was associated with lower rates of adverse events                   gating a NOAC (very low-dose edoxaban, 15 mg once daily) in the
across frailty levels, however residual confounding could not be fully             elderly Japanese patients with AF deemed unsuitable for standard
excluded.159                                                                       OAC therapy. In this trial, the use of edoxaban was associated
Expert consensus document on the management of arrhythmias in frailty syndrome                                                                         1267


with a 4.4%/year absolute risk reduction in stroke at the cost of a
non-significant absolute increase in 1.5%/year of major bleeding.163
                                                                             • A prospective study systematically evaluating the frail status in pa­
                                                                                 tients undergoing LAA closure is needed to assess the relationship
   In older patients, the prevalence of cerebral amyloid angiopathy              between frailty and treatment outcomes and benefits.
and cerebral microbleeds on MRI is high, and indicates increased             •   Further research is needed for the efficacy and safety of left atrial ap­
risk of intracerebral haemorrhage and is often considered a contra­              pendage occluders in high-risk patients (with contraindications for
indication for anticoagulation.134,160 Whether this risk is lower and            oral anticoagulation) vs. best medical care.
the net clinical benefit sufficient to initiate anticoagulation remains




                                                                                                                                                              Downloaded from https://academic.oup.com/europace/article/25/4/1249/7036349 by Uniwersytet Jagiellonsky w Krakowie user on 05 August 2024
unknown, it is advisable to discuss this opportunity on an individual            Consensus statements
basis.132
   Importantly, frail AF patients considered for OAC require a de­               • In all AF patients with non-sex-related CHA DS -VASc
                                                                                                                                     2    2
                                                                                     stroke risk factor(s) OAC therapy is beneficial,
tailed assessment of their baseline risk profile and personal values
                                                                                     irrespective of their frailty status.
and preferences, as well a frequent clinical follow-up. Patient compli­
ance and adherence, particularly to the twice daily regime, should be            •   Frail AF patients require a detailed assessment of their
assessed at the initiation of therapy and monitored.                                 baseline stroke and bleeding risk profile and consideration
                                                                                     of their personal values and preferences with regard to AF
                                                                                     management.
Left atrial appendage occlusion
In general, the most common justification for left atrial (LAA) closure          • Frailty, cognitive decline and risk of falling is not generally a
over systemic OAC is high bleeding risk (e.g. due to falls, liver and kid­           reason not to anticoagulate patients
ney dysfunction, polypharmacy and drug interaction) or absolute                  • Frail AF patients taking OAC need a frequent, regular
contraindications to systemic OAC, with frail patients being particu­                clinical follow-up for treatment effects monitoring and
larly vulnerable. The decision-making is hindered by insufficient high-              stroke and bleeding risk re-assessment.
quality prospective data comparing LAA occlusion devices with                    • The advantages of NOACs relative to VKAs are likely
NOACs and the need for antithrombotic therapy after implant                          consistent in frail and non-frail AF patients, but frail AF
and by lack of systematic experience of such an intervention in frail                patients may have a greater absolute benefit from NOACs
patients, although, according to recent Medicare database analysis,                  owing to a higher absolute risk of thromboembolic events
nearly half the patients who underwent LAA closure were consid­                      in frail AF patients.
ered frail at intermediate or high levels of frailty.164 At present, the         • Formal frailty assessment of patients prior to LAA closure
ESC Guidelines restrict their recommendations for LAA closure                        may provide important additional information on
therapy to patients with contraindications for long-term OAC, for                    treatment outcomes and the need for correction of
example, intracranial bleeding without a reversible cause and to pa­                 identified deficits and more thorough follow-up.
tients undergoing cardiac surgery who could have simultaneous sur­               • Aspirin should not be used for stroke prevention in frail
gical LAA occlusion or exclusion.134                                                 patients with AF, since it is essentially ineffective and
    Although the peri-procedural complications and mortality asso­                   associated with similar risk of bleeding compared with
ciated with percutaneous LAA closure is likely to be higher in frailty,              NOACs or VKAs.
this therapy may benefit frail patients in the long-term as analysis of
the Medicare database has recently demonstrated. It included 21 787
patients aged 65 years and older who underwent LAA closure,
10 740 (49.3%) of whom were considered frail based on the                    Ablation: indications and outcome
Hospital Frailty Risk Score (HFRS) >5; 33.5% were regarded as inter­         The frail state, with associated risk factors, can also negatively impact
mediate (HFRS 5–15) and 15.8% as high risk (HFRS >15). HFRS was              clinical decisions regarding use of more aggressive therapies such as non-
calculated on the basis of 109 International Classification of Diseases,     pharmacologic interventions, AAD therapy, and anticoagulation.165,166
Tenth Revision, Clinical Modification secondary diagnosis codes from         Ablation therapies include AV node ablation and pacing (which has
all hospitalizations occurring at least 1 year before the date of admis­     been used predominantly in older patients) and left atrial ablation aiming
sion for the index hospitalization or using secondary diagnosis codes        at rhythm control. Ablation if successful in selected patients with symp­
during the index admission.                                                  tomatic AF can provide a durable long-term rhythm benefit without the
    HFRS >15 was associated with 8.3-fold increased risk of long hos­        need for AADs therapies.167 Some insight regarding procedural benefit
pital stay (>10 days) and 1.8 times and nearly 5.7 times higher 30-day       of ablation can be gleaned from examining catheter ablation outcomes
readmission and 30-day mortality, respectively, compared with HFRS           in the very aged. Age alone is a significant risk factor for AF recurrence
<5. One-year mortality was increased by 2.8-fold in the high risk            after ablation in older patients.168 In patients with successful ablation,
group. The one-year mortality rates (8.2%) in frail patients were            the long-term rates of stroke are relatively low across all age groups
nearly three- to four-fold higher than reported in the                       and associated risk factor profiles. In this regard, patient selection
PROTECT-AF (2.5%) and PREVAIL (3.0%) trials.164                              who may benefit from ablation becomes critical.
                                                                                 In observational studies that examined ablation in patients >80
                                                                             years of age, catheter ablation was safe and effective compared
Knowledge gaps                                                               with younger patients. In octogenarian patients, despite more coex­
• More high-quality data are needed to inform optimal management of          isting cardiovascular diseases, 1-year survival free of arrhythmias was
   stroke risk in frail AF patients.                                         78% vs. 75% in younger patients.169 In another study, over a follow-
1268                                                                                                                                      I. Savelieva et al.



up of 18 ± 6 months, 68% of octogenarians were free of AF
compared with 71% of patients that were <80 years of age.                        • In the majority of frail patients, pharmacological rate
                                                                                     control is a preferred option, based on the net clinical
In both groups additional procedures increased long-term AF free
                                                                                     benefit, However, an individualized decision process—
success rates to 87%.170 In both studies severe complication rates
                                                                                     patient centred—considering the risk/benefit of each
were not increased in the older groups. Other studies have
                                                                                     therapeutic regimen and patient preference should take
addressed slightly younger populations (75 years and older) de­
                                                                                     place.
monstrating an 86% efficacy rate at 1 year and 52–59% efficacy at




                                                                                                                                                                Downloaded from https://academic.oup.com/europace/article/25/4/1249/7036349 by Uniwersytet Jagiellonsky w Krakowie user on 05 August 2024
3–5 years.171–173 However, older patients are more likely to have
non-paroxysmal AF and non-pulmonary vein triggers requiring
more extensive left atrial ablation and/or repeated procedures.169             Silent arrhythmias and screening for AF
   There is limited evidence from retrospective reports that some              AF may often be asymptomatic in up to 40% of cases175 or it may
degree of frailty may not be uncommon in patients undergoing AF                present atypical symptoms (in around 25% of cases).176
ablation and that it is associated with higher mortality and adverse           Asymptomatic AF has a higher prevalence in older subjects with per­
outcomes after ablation. Using HFRS calculated from ICD-10 diag­               manent AF and is associated with more complex clinical conditions,
nostic codes, 38.6% out of 5070 in-patients treated with catheter ab­          in terms of comorbidities, that condition a higher thromboembolic
lation were defined as frail with HFRS >5 including 8,3% including             risk, resulting in a higher risk of stroke, as well as of cardiovascular
8.3% at high risk (HFRS >15).172 Frailty was independently associated          and all-cause mortality compared with symptomatic AF.177
with length of stay, post-procedure 30-day mortality, and 30-day re­              Detection of asymptomatic (‘silent’) AF, and prescription of oral
admission rates. The long-term mortality (up to 630 days) was 5.8%             anticoagulants in patients at risk of thromboembolic events is the tar­
in the low-risk group, 23.4% in the intermediate-risk group (HFRS 5-           get of opportunistic screening.134 There is evidence that pharmacy-
15), and 42.2% in the high-risk group. In propensity score matching            based, automated AF screening in elderly citizens identified subjects
analysis, frail patients did not benefit from ablation with respect to         with unknown AF and an excess mortality risk over the next year.178
HF admissions or stroke as opposed to their non-frail                          A large variety of devices are currently available for AF screening.179
counterparts.173                                                               An important aspect of screening is also detection of undertreated
   These observational studies represent selected elderly AF patients          known AF, which may be particularly common among frail patients
that were felt to be candidates for the procedure, but in aggregate            who often do not receive appropriate therapy because of unrecog­
provide evidence of procedural benefit when ideal candidates are               nized AF in 40–50%.180
identified. The CABANA trial randomized 2204 AF patients age                      Atrial high-rate episodes (AHREs) detected by CIEDs are usually
>65 years, or <65 years with ≥1 risk factor for stroke to antiarrhyth­         discovered during routine device follow-up and classified in terms
mic/rate control drugs vs. catheter ablation. In the intention-to-treat        of duration of the single episode or time spent in atrial tachyarrhyth­
analysis, the primary endpoint of all-cause mortality, disabling stroke,       mias during a day.181,182 These extended diagnostic capabilities have
serious bleeding or cardiac arrest (primary endpoint) by                       led to new terms, such as ‘AF burden’, defined as the overall time
intention-to-treat trended towards harm with ablation in those pa­             spent in AF during a specified period of time, and ‘subclinical AF’, cor­
tients >75 years of age [HR 1.46 (95% CI: 0.80–2.67)], however those           responding to episodes of atrial tachyarrhythmias with duration be­
>75 years of age still were much more likely to remain in sinus rhythm         tween 5 min and 24 h, detected by a CIED in patients without clinical
compared with medications [HR 0.48 (95% CI: 0.33–0.68)].174                    history or clinical symptoms of AF.181
   Clearly, some patients, particularly those with multiple other med­            The prevalence of AHREs or AF burden, among patients im­
ical conditions, are reluctant to consider a major procedure and have          planted with CIEDs varies, depending on underlying heart disease,
a strong preference for a pharmacological approach. A shared                   periods of observation, and above all previous history of clinically
decision-making process is critical in these patients as the disease           overt atrial tachyarrhythmias, including AF.183 An analysis of all the
management is navigated.                                                       data from the literature reveals that that AHREs with a duration
                                                                               >5–6 min are common in patients implanted with CIEDs, with an in­
                                                                               cidence between 10 and 68%.184
Knowledge gaps
                                                                                  The association between CIED-detected atrial tachyarrhyth­
• There is insufficient data on the effect of ablation on mortality, bleed­    mias of variable durations and stroke or systemic thromboembol­
    ing, and stroke in older patients with multiple comorbidities/pre-frail/   ism has been evaluated by several studies that overall collected
    frail state.                                                               data on >22,000 patients. It has been shown that AHRE burden
•   Appropriate timing of ablation needs better criteria because older
                                                                               with a duration ≥5–6 min is significantly associated with increased
    patients are often diagnosed late due to lack of symptoms.
                                                                               risk of stroke or systemic thromboembolism, with a hazard ratio
•   Type of ablation (pulmonary vein isolation, substrate-based ablation)
                                                                               ranging between 2 and 9.180,184 However, risk of stroke for sub­
    is not established in the presence of age-related atrial remodelling.
                                                                               clinical AF is around 2.4-fold, i.e. lower than what traditionally re­
    Consensus statements                                                       ported for clinical AF (4.8-fold).185 Therefore, the clinical
                                                                               significance of CIED-detected AHREs with regard to prescription
    • Catheter ablation may be beneficial in selected old and                  of anticoagulants in terms of risk benefit ratio is currently investi­
       very old patients, particularly if this a patient’s choice and          gated in prospective trials. The randomized controlled LOOP
       provided that improvement in symptoms and quality of                    study has shown that in individuals 70 years of age and older
       life is expected.                                                       with risk factors for stroke, screening using ILR devices increased
Expert consensus document on the management of arrhythmias in frailty syndrome                                                                 1269


the likelihood of AF detection by three-fold accompanied by initi­          with an initial haemorrhagic stroke192 or a high burden of cerebral
ation of OAC therapy, but this strategy was not associated with             microbleeds.193
any significant reduction in rates of stroke or systemic
embolism.186                                                                Implications for acute management and
   Current evidence suggests that a patient-tailored decision-making,       chronic anticoagulation
particularly in frail patients, is useful when deciding to anticoagulate    There is no strong evidence of a net benefit from anticoagulation
subjects with AHREs. This approach includes continued patient               during the first 14 days after cardioembolic stroke,194 although




                                                                                                                                                         Downloaded from https://academic.oup.com/europace/article/25/4/1249/7036349 by Uniwersytet Jagiellonsky w Krakowie user on 05 August 2024
follow-up, also using remote monitoring of the CIED, targeted to de­        acute anticoagulation appears relatively safe after minor cardioem­
tect the development of clinical AF, to monitor the evolution of            bolic stroke.195 A reasonable approach is to initiate anticoagulation
AHRE or AF burden and specifically the transition to AHRE lasting           within 14 days for most cardioembolic strokes but delay initiation
more than 24 h, onset or worsening of HF, or any clinical change            until after 14 days if there is a large infarct, haemorrhagic trans­
that might suggest a change in clinical conditions.187,188                  formation on neuroimaging, or uncontrolled hypertension.196
                                                                            No good evidence exists to support a different balancing approach
                                                                            in frail patients.
   Consensus statements
                                                                                There are few robust data specifically in frail patients regarding
                                                                            chronic anticoagulation for thromboembolism prevention in AF.
  • Asymptomatic (‘silent’) AF detected occasionally and                    Advancing age is more strongly associated with thromboembolism
      lasting at least 30 s is not a benign condition and requires
      the same clinical evaluations, with regard to risk                    than bleeding197 and the net clinical benefit of anticoagulation in­
      stratification for stroke and prescription of                         creases with age.198 Although physicians hesitate to anticoagulate old­
      antithromboembolic prophylaxis (based on the                          er patients given fears about falls and intracranial haemorrhage,
      CHA2DS2-VASc score), of symptomatic AF                                anticoagulation provides a net benefit even in patients with frequent
                                                                            falls.199 There are anticoagulant drugs available that have a similar risk
  • Screen-detected AF, as a result of ECG screening or ECG                 of bleeding as aspirin even in vulnerable patients such as those with
      confirmation as a result of pulse palpation, BP
      measurement, or apps available in smartphones or
                                                                            prior ischaemic stroke.200 These factors support treating frail patients
                                                                            with anticoagulation as otherwise indicated for non-frail patients.
      watches, is not a benign condition, and after appropriate
      clinical evaluation and risk stratification for stroke,
                                                                               Consensus statement
      consideration of antithromboembolic prophylaxis is
      justified
                                                                              • Until further data are available, frail AF patients should
  • In patients with a cardiac implantable electronic device                      receive anticoagulation as otherwise indicated for
      (CIED) with device-detected atrial tachyarrhythmias                         non-frail patients.
      (AHREs) a complete cardiological evaluation is
      indicated, with 12-lead ECG, general assessment of
      clinical conditions and clinical risk stratification for
      thromboembolic risk.                                                  Orthostatic hypotension and
  • In patients with CIED-detected AHRE, continued patient                  syncope syndrome
      follow-up—including remote monitoring—is advised to
      detect the development of clinical AF, to monitor the                 Carotid hypersensitivity syndrome
      evolution of AHRE or AF burden and specifically the                   Carotid sinus syndrome (CSS) is a form of reflex syncope charac­
      transition to AHRE lasting more than 24 h, onset or                   terized by bradycardia and hypotension. The syndrome is almost
      worsening of HF, or any variation that might suggest a                exclusively diagnosed in older (male) patients and rare before the
      change in clinical conditions, as the basis for                       age of 40 years. Because a hypersensitive response is present in
      patient-tailored consideration of oral anticoagulants.                up to 30% of older patients with syncope, it is recommended
                                                                            that patients above 50 years of age who present with unexplained
                                                                            falls or syncope should have carotid sinus massage (CSM) per­
                                                                            formed using particular attention in those at risk of neurologic
Stroke as a frailty component and                                           events.32 The diagnosis requires reproduction of spontaneous
                                                                            symptoms during asystole and/or a vasodepressor response.32
specific characteristics in the very                                        One-third of patients with a hypersensitive response (CSH) to
elderly                                                                     CSM present with unexplained falls; amnesia for loss of conscious­
                                                                            ness can be reproduced during CSM in such patients.201 The finding
Ischaemic vs. haemorrhagic stroke risk                                      of a hypersensitive response should not preclude further investiga­
Frail patients face a heightened risk of stroke because they have a         tion for other causes of syncope. One-third of CSH patients have
substantial burden of vascular risk factors and their clinicians hesitate   other reflex or cardiac abnormalities; conversely, in 80 previously
to treat them with antithrombotic drugs.189 Frail patients have worse       asymptomatic individuals, CSH was present in 28 (35%) and accom­
outcomes than other stroke patients,190 and stroke worsens                  panied by symptoms in 10.202 The 95th percentile for CSM re­
frailty.191 Most strokes in AF patients are ischaemic, even in those        sponse in a large random community cohort, mean age 75 years
1270                                                                                                                                                      I. Savelieva et al.



 Table 5 Syndromes of orthostatic intolerance

  Syndrome         Test                   Time to              Pathophysiology                         Symptoms                             Associated Conditions
                                          abnormal BP
                                          response
  ...........................................................................................................................................
  Initial OH       Beat-to-beat BP        0–15 s               Transient mismatch                      Light-headedness, dizziness,         Old age, drug-induced




                                                                                                                                                                                Downloaded from https://academic.oup.com/europace/article/25/4/1249/7036349 by Uniwersytet Jagiellonsky w Krakowie user on 05 August 2024
                      on active                                   between cardiac output and               visual disturbances                (alpha-blockers)
                      standing test                               total peripheral resistance              few seconds after standing.
  Classical        Active standing        <3 min               Impaired total peripheral               Dizziness, light-headedness,         Frailty, drug-induced
    OH               test; TT                                    resistance and HR increase in           weakness, visual and hearing         (vasoactive drugs,
                                                                  autonomic failure; severe                disturbances                       diuretics), autonomic
                                                                  volume depletion                                                            failure, hypovolaemia
  Delayed          TT                     >3 min               Likely progressive fall in venous       Prolonged prodromes: dizziness,      Frailty, incipient autonomic
     OH                                                           return and low cardiac output            light-headedness, visual and       failure, drug-induced
                                                                                                           hearing disturbances, low back     (vasoactive drugs and
                                                                                                           pain, neck or precordial pain      diuretics), comorbidity

 BP, blood pressure; ESC, European Society of Cardiology; OH, orthostatic hypotension; TT, tilt testing.
 Adapted from 2018 ESC Guidelines for the diagnosis and management of syncope.32




was 7.3 s asystole and a 77 mmHg drop in systolic BP,202 suggesting                          between syncope and other clinical conditions causing unexplained
these thresholds for diagnosis and intervention.203                                          falls.
                                                                                                 Older patients are more likely to receive an ILR, because of
                                                                                             higher rate of structural and electrical heart disease, limited value
Orthostatic intolerance syndrome
                                                                                             of the clinical history in determining the syncope aetiology, lack of
Orthostatic intolerance syndrome is characterized by the abnormal,
                                                                                             prodromal symptoms and higher risk of trauma. ILR may be useful
progressive and sustained drop of systolic and diastolic pressure ≥20
                                                                                             in distinguishing between syncope, unexplained falls and epileptic
and ≥10 mmHg, respectively, or the decrease in systolic pressure to
                                                                                             seizures.36 In the last few years, technology has allowed to intro­
<90 mmHg.32 It can be classified into initial, classical and delayed
                                                                                             duce the use of smartwatches in automatic Fall Detection
orthostatic hypotension, according to the time of the onset of the
                                                                                             Systems. Benefits in terms of quickness of intervention derive
abnormal pressure changes, as described in Table 5.
                                                                                             from the widespread acceptance, low cost and networking inter­
                                                                                             faces of the devices, even if some methodologic aspects are still
Investigations and management                                                                to be improved.
The diagnostic pathway proposed by the ESC guidelines on syn­                                    In older patients with vasodepressor reflex syncope, the recur­
cope,32 was used also in older patients, enabling a reduction of unex­                       rence of syncope/pre-syncope may be reduced by discontinuing/re­
plained syncope to around 10%.204 The initial evaluation relies on                           ducing vasoactive therapy, without higher adverse events, aimed at
clinical history, physical examination, active standing test, and                            achieving an average systolic BP around 140 mmHg, or not
12-lead ECG. Physicians should search for systemic diseases, physical                        <130 mmHg, as recommended in older and frail adults.208,209
frailty and locomotor disabilities. Details of cognitive status, social cir­                 Medical therapy for orthostatic intolerance includes midodrine,
cumstances, injuries, impact of syncope on basal/instrumental activ­                         droxidopa, fludrocortisone and piridostigmine, considering supine
ities of daily living, should be recorded. Possible witnesses should                         hypertension.32,210 Additionally, isometric physical counter-
be interview, because retrograde amnesia is frequent in older and frail                      pressure manoeuvres, and support stockings or abdominal binders
patients. A careful observation of gait and standing balance to assess                       to reduce venous pooling, may find an indication to prevent
the risk of falling is mandatory.32 Given the high prevalence of CSS in                      recurrences.32
the elderly, the CSM may be performed initially. Even if very rarely                             Despite the lack of data on syncope, a comprehensive assessment
(0.24%), the manoeuvre can be complicated by cerebrovascular                                 on cognitive status and physical frailty, may help in the selection of
events. For this reason, it is advised that CSM is undertaken with cau­                      patients for cardiac pacing. According to current ESC Guidelines,
tion in subjects with a previous TIA or stroke, or when a carotid sten­                      dual-chamber cardiac pacing should be considered in subjects with
osis >70% is present.32 The clinical history has a limited value in the                      a reflex, asystolic, syncope. A similar level of recommendation can
differential diagnosis between cardiac and neurally mediated causes                          be found also when a cardioinhibitory reflex is dominant in a
of syncope in older patients,205 thus tilt testing (TT) and CSM are es­                      tilt-induced vasovagal syncope and in a CSS. However, it should be
sential diagnostic steps.                                                                    taken into account that the device can significantly reduce the burden
    TT was validated in older subjects206 and is well tolerated, even in                     of events, but not prevent all of them. Therapy should be also limited
the oldest old.207 TT may detect hypotensive susceptibility, initial and                     to subjects ≥40 years, presenting recurrent episodes with a signifi­
delayed orthostatic hypotension and guide the differential diagnosis                         cant impact on social and active life, when alternative treatment failed
Expert consensus document on the management of arrhythmias in frailty syndrome                                                                    1271


or were not feasible.213 Moreover, pacing for these specific indica­           Development of a specialist team and
tions can be found further limitations in older frail individuals.
                                                                               aftercare
                                                                               Respondents of a recent EP Wire,43 preferred an ‘Arrhythmia Team’
Improving patient outcome:                                                     consisting of an electrophysiologists, clinical cardiologists, geriatri­
                                                                               cians, internists, palliative care specialists, nurses and family mem­
specific consideration                                                         bers/carers to manage frail patients. In addition, the specialist team
                                                                               should also include specialist nurses, occupational therapists, phy­




                                                                                                                                                             Downloaded from https://academic.oup.com/europace/article/25/4/1249/7036349 by Uniwersytet Jagiellonsky w Krakowie user on 05 August 2024
Quality of life
                                                                               siotherapists/exercise physiologists, general practitioners, pharma­
Frailty results in diminished physical, emotional, and social functioning
                                                                               cists, and social workers. Composition of the team is largely
which significantly impacts quality of life.211,212 For most frail patients,
                                                                               dependent on the individual needs of the patient; ideally input and
their desired goals from therapy are improvements in functional sta­
                                                                               care would be provided by all appropriate experts. Ongoing care
tus and quality of life, rather than extending life; these patient-
                                                                               for frail patients with cardiac arrhythmias is probably best managed
centred outcomes should be incorporated into the treatment
                                                                               by specialist nurse-led aftercare in the community, with appropriate
decision-making process. There is currently a paucity of research
                                                                               access and referral to a multidisciplinary Arrhythmia team, as
specifically examining the impact of frailty per se on quality of life
                                                                               required.
in patients with cardiac arrhythmias.
                                                                                  Nurses and specialist nurses have an important role in providing a
   Frailty significantly impacts treatment choices, with frail patients
                                                                               person-centred holistic approach to managing patients with frailty
with cardiac arrhythmias less likely to be aggressively treated com­
                                                                               syndrome, monitoring and timely identifying changes in components
pared with their non-frail counterparts.166 For example, frail AF pa­
                                                                               of frailty syndrome such as assessment of nutrition, pharmacother­
tients are less likely to receive oral anticoagulation,213–215 primarily
                                                                               apy, adherence to treatment, falls risk, exercise, and mood and cog­
due to physicians’ fears of bleeding related to frailty-associated char­
                                                                               nitive impairment, and prompting interventions to minimize further
acteristics (risk of falls and cognitive impairment) and are also less
                                                                               weight loss, loss of muscle mass and strength, and reduce fall risk fac­
likely to receive a rhythm-control strategy.43,216 There is also contro­
                                                                               tors to help maintain a state of homeostasis.3
versy regarding the use of ICDs in frail individuals given the increased
                                                                                  Patient education and active involvement in decision-making are
risk of non-cardiac death in frail patients that may diminish the ben­
                                                                               important for good adherence to OAC and optimal treatment ef­
efits of the ICD.217,218 However, some types of devices, may be im­
                                                                               fects.223 In addition, various decision supporting tools (built in elec­
portant therapies in frail patients given their impact on outcomes of
                                                                               tronic medical records or mobile applications) have been shown
significance to patients. For example, CRT improves functional cap­
                                                                               to improve stroke risk management in AF patients.224,225
acity, with consequent improvements in physical and cognitive func­
tioning,120,219 whilst pacemaker implantation for bradyarrhythmias
decreases the risk of falls and reduces frailty,220 in addition to pre­        Digital technology and eHealth
venting onset or worsening of HF, all of which are likely to positively        Frail patients who require long-term care with frequent assessment
impact overall quality of life.                                                of health state may benefit from digital health technologies (tele­
                                                                               health, mHealth, and wearables such as heart rate and activity track­
Care models                                                                    ing and biological sensors).4 These technologies allow for for
Research suggests that there is little or no evidence for routine compre­      detection and monitoring components of frailty syndrome such as
hensive screening for unmet health needs in the older population.221,222       physical activity, gait speed, postural changes and falls, heart rate
Targeted approaches are better, to identify ‘at-risk’ groups of indivi­        and fitness, arrhythmias, and assist in early identification of subclinical
duals, with care models focussing on reversing modifiable elements of          deterioration in health. Cognitive, visual, or sensory impairments
frailty, particularly addressing underlying medical conditions causing         may potentially be assessed through telehealth or mHealth.
and/or contributing to frailty and optimizing management and reviewing         Telemedicine may enable high-quality and cost-efficient care for an
medication, to stabilize the underlying disease processes.                     increasing number of patients with frailty. For example, mHealth
   The fundamental issue is that healthcare professionals need to rec­         has become an important component of many AF outpatient clinics
ognize frailty as they are often focussed on specific diseases/co­             in the light of the COVID-19 pandemic and decreased capacity to see
morbidities and these may mask frailty. Education of healthcare                patients in the outpatient clinic.226 Several validated mHealth solu­
professionals is needed to highlight the components of frailty, to ac­         tions are available for remote heart rate and rhythm monitoring as
knowledge that frailty is a dynamic process, and demonstrate how to            well as for risk factor assessment.227–229
optimize management of this vulnerable patient group. Identification
of frailty with an appropriate tool (see Section ‘Assessment of frailty        Acknowledgement
and frailty scores’) should be the first step and if identified, further       The authors thank the EHRA Scientific Document Committee: Dr
comprehensive assessment (by a geriatrician) should be undertaken.             Nikolaos Dagres, Prof. Thomas Deneke, Prof. Arthur Wilde, Prof.
The concept of frailty requires a more holistic approach rather than a         Frank R. Heinzel, Prof. Christian Meyer, Prof. Lucas Boersma, Prof.
                                                                               Radoslaw Lenarczyk, Prof. Luigi di Biase, Dr Elena Arbelo, Dr Avi
disease-based medical approach and should integrate health and so­
                                                                               Sabbag, Prof. Pierre Jais, Prof. Milos Taborsky, Asso. Prof. Markus
cial care and take into consideration the outcomes of importance to
                                                                               Stühlinger.
patients and their families/carers. As such, this approach requires
multidisciplinary interventions and the support and input from a               Conflicts of interest: The authors have provided declaration of inter­
multidisciplinary team.                                                        est information for all relationships that might be perceived as real or
1272                                                                                                                                                                I. Savelieva et al.



potential sources of conflicts of interest. The full disclosures can be                      23. Denfeld QE, Winters-Stone K, Mudd JO, Gelow JM, Kurdi S, Lee CS. The preva­
viewed in the supplementary material for this article.                                           lence of frailty in heart failure: a systematic review and meta-analysis. Int J Cardiol
                                                                                                 2017; 236:283–9.
                                                                                             24. Zhang Y, Yuan M, Gong M, Tse G, Li G, Liu T. Frailty and clinical outcomes in heart
                                                                                                 failure: a systematic review and meta-analysis. J Am Med Dir Assoc 2018; 19:1003–8.
Supplementary material                                                                       25. Ethun CG, Bilen MA, Jani AB, Maithel SK, Ogan K, Master VA. Frailty and cancer:
                                                                                                 Implications for oncology surgery, medical oncology, and radiation oncology. CA
Supplementary material is available at Europace online.                                          Cancer J Clin 2017; 67:362–77.
                                                                                             26. Orum M, Gregersen M, Jensen K, Meldgaard P, Damsgaard EMS. Frailty status but




                                                                                                                                                                                            Downloaded from https://academic.oup.com/europace/article/25/4/1249/7036349 by Uniwersytet Jagiellonsky w Krakowie user on 05 August 2024
                                                                                                 not age predicts complications in elderly cancer patients: a follow-up study. Acta
References                                                                                       Oncologica 2018; 57:1458–66.
                                                                                             27. Ruiz J, Miller AA, Tooze JA et al. Frailty assessment predicts toxicity during first cy­
  1. https://www.who.int/health-topics/ageing
  2. Walker DM, Gale CP, Lip G, Martin-Sanchez FJ, McIntyre HF, Mueller C, et al.                cle chemotherapy for advanced lung cancer regardless of chronologic age. J Geriatr
     Frailty and the management of patients with acute cardiovascular disease: a position        Oncol 2019; 10:48–54.
     paper from the Acute Cardiovascular Care Association. Eur Heart J Acute Cardiovasc      28. Edwards BJ, Zhang X, Sun M, Song J, Khalil P, Karuturi MS, et al. Overall survival in
     Care 2018; 7:176–93.                                                                        older patients with cancer. BMJ Support Palliat Care 2020; 10:25–35.
  3. Vitale C, Jankowska E, Hill L, Piepoli M, Doehner W, Anker SD, et al. Heart Failure     29. Cheng MH, Chang SF. Frailty as a risk factor for falls among community dwelling
     Association/European Society of Cardiology position paper on frailty in patients            people: evidence from a meta-analysis. J Nurs Scholarsh 2017; 49:529–36.
     with heart failure. Eur J Heart Fail 2019; 21:1299–305.                                 30. Panel on Prevention of Falls in Older Persons, American Geriatrics Society and
  4. Richter D, Guasti L, Walker D, Lambrinou E, Lionis C, Abreu A, et al. Frailty in car­       British Geriatrics Society. Summary of the updated American Geriatrics Society/
     diology: definition, assessment and clinical implications for general cardiology. A         British Geriatrics Society clinical practice guideline for prevention of falls in older
     consensus document of the Council for Cardiology Practice (CCP), Acute                      persons. J Amer Geriatr Soc 2011; 59:148–57.
     Cardiovascular Care Association (ACCA), Association of Cardiovascular Nursing           31. Bhangu J, Hall P, Devaney N, Bennett K, Carroll L, Kenny RA, McMahon CG. The
     and Allied Professions (ACNAP), European Association of Preventive Cardiology               prevalence of unexplained falls and syncope in older adults presenting to an Irish
     (EAPC), European Heart Rhythm Association (EHRA), Council on Valvular                       urban emergency department. Eur J Emerg Med 2019; 26:100–4.
     Heart Diseases (VHD), Council on Hypertension (CHT), Council of Cardio-                 32. Brignole M, Moya A, de Lange FJ, Deharo JC, Elliott PM, Fanciulli A, et al. 2018 ESC
     Oncology (CCO), Working Group (WG) Aorta and Peripheral Vascular                            Guidelines for the diagnosis and management of syncope. Eur Heart J 2018; 39:
     Diseases, WG e-Cardiology, WG Thrombosis, of the European Society of                        1883–948.
     Cardiology, European Primary Care Cardiology Society (EPCCS). Eur J Prev                33. Goldstein DS, Sharabi Y. Neurogenic orthostatic hypotension: a pathophysiological
     Cardiol 2022; 29:216–27.                                                                    approach. Circulation 2009; 119:139–46.
  5. Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. Lancet   34. Bhangu J, McMahon CG, Hall P, Bennett K, Rice C, Crean P, et al. Long-term cardiac
     2013; 381:752–62.                                                                           monitoring in older adults with unexplained falls and syncope. Heart 2016; 102:
  6. O’Caoimh R, Galluzzo L, Rodríguez-Laso Á, Van der Heyden J, Ranhoff AH,
                                                                                                 681–6.
     Lamprini-Koula M, et al. Prevalence of frailty at population level in European
                                                                                             35. Maggi R, Rafanelli M, Ceccofiglio A, Solari D, Brignole M, Ungar A. Additional diag­
     ADVANTAGE Joint Action Member States: a systematic review and meta-analysis.
                                                                                                 nostic value of implantable loop recorder in patients with initial diagnosis of real or
     Ann Ist Super Sanita 2018; 54:226–38.
                                                                                                 apparent transient loss of consciousness of uncertain origin. Europace 2014; 16:
  7. Walston J, Robinson TN, Zieman S, et al. Integrating frailty research into the med­
                                                                                                 1226–30.
     ical specialties-Report from a U13 Conference. J Am Geriatr Soc 2017; 65:2134–9.
                                                                                             36. Brignole M, Vardas P, Hoffman E, Huikuri H, Moya A, Ricci R, et al. Indications for
  8. Collard RM, Boter H, Schoevers RA, Oude Voshaar RC. Prevalence of frailty in
     community-dwelling older persons: a systematic review. J Am Geriatr Soc 2012;               the use of diagnostic implantable and external ECG loop recorders. Europace 2009;
     60:1487–92.                                                                                 11:671–87.
  9. O’Caoimh R, Sezgin D, O’Donovan MR, Molloy DW, Clegg A, Rockwood K, Liew                37. Homann B, Plaschg A, Grundner M, Haubenhofer A, Griedl T, Ivanic G, et al. The
     A. Prevalence of frailty in 62 countries across the world: a systematic review and          impact of neurological disorders on the risk for falls in the community dwelling eld­
     meta-analysis of population-level studies. Age Ageing 2021; 50:96–104.                      erly: a case-controlled study. BMJ Open 2013; 3:e003367.
 10. Strandberg TE, Lindström L, Jyväkorpi S, Urtamo A, Pitkälä KH, Kivimäki M.              38. Johnell K, Jonasdottir Bergman G, Fastbom J, Danielsson B, Borg N, Salmi P.
     Phenotypic frailty and multimorbidity are independent 18-year mortality risk indi­          Psychotropic drugs and the risk of fall injuries, hospitalisations and mortality among
     cators in older men: The Helsinki Businessmen Study (HBS). Eur Geriatr Med 2021;            older adults. Int J Geriatr Psychiatry 2017; 32:414–20.
     12:953–61.                                                                              39. Lipardo DS, Aseron AMC, Kwan MM, Tsang WW. Effect of exercise and cognitive
 11. Fried LP, Tangen CM, Walston J et al. Frailty in older adults: evidence for a pheno­        training on falls and fall-related factors in older adults with mild cognitive impair­
     type. J Gerontol A Biol Sci Med Sci 2001; 56:M146–56.                                       ment: a systematic review. Arch Phys Med Rehabil 2017; 98:2079–96.
 12. Mitnitski AB, Mogilner AJ, Rockwood K. Accumulation of deficits as a proxy meas­        40. Chan WC, Yeung JWF, Wong CSM, Lam LCW, Chung KF, Luk JKH, et al. Efficacy of
     ure of aging. Scientific World Journal 2001; 1:323–36.                                      physical exercise in preventing falls in older adults with cognitive impairment: a sys­
 13. Rockwood K, Howlett SE. Fifteen years of progress in understanding frailty and              tematic review and meta-analysis. J Am Med Dir Assoc 2015; 16:149–54.
     health in aging. BMC Med 2018; 16:220.                                                  41. Parry SW, Bamford C, Deary V, Finch TL, Gray J, MacDonald C, et al. Cognitive–
 14. Rockwood K, Stadnyk K, MacKnight C, McDowell I, Hébert R, Hogan DB. A brief                 behavioural therapy-based intervention to reduce fear of falling in older people:
     clinical instrument to classify frailty in elderly people. Lancet 1999; 353:205–6.          therapy development and randomised controlled trial – the Strategies for
 15. Rasiah J, Cummings GG, Gruneir A, D Oelke ND, Estabrooks C, Holroyd-Leduc J.                Increasing Independence, Confidence and Energy (STRIDE) study. Health Technol
     Prefrailty in older adults: a concept analysis. Int J Nurs Stud 2020; 108:103618.
                                                                                                 Assess 2016; 20:1–206.
 16. Ofori-Asenso R, Chin KL, Mazidi M, Zomer E, Ilomaki J, Zullo AR, et al. Global in­
                                                                                             42. Herr M, Robine JM, Pinot J Arvieu JJ, Ankri J. Polypharmacy and frailty: prevalence,
     cidence of frailty and prefrailty among community-dwelling older adults: a system­
                                                                                                 relationship, and impact on mortality in a French sample of 2350 old people.
     atic review and meta-analysis. JAMA Netw Open 2019; 2:e198398.
                                                                                                 Pharmacoepidemiol Drug Saf 2015; 24:637–46.
 17. Chamberlain AM, Finney Rutten LJ, Manemann SM, et al. Frailty trajectories in an
                                                                                             43. Fumagalli S, Potpara TS, Bjerregaard Larsen T, Haugaa KH, Dobreanu D, Proclemer
     elderly population-based cohort. J Am Geriatr Soc 2016; 64:285–92.
                                                                                                 A, et al. Frailty syndrome: an emerging clinical problem in the everyday management
 18. Fried LP FL, Darer J, Williamson JD, Anderson G. Untangling the concepts of dis­
     ability, frailty, and comorbidity: implications for improved targeting and care. J          of clinical arrhythmias. The results of the European Heart Rhythm Association sur­
     Gerontol A Biol Sci Med Sci 2005:255–63.                                                    vey. Europace 2017; 19:1896–902.
 19. McGeorge SJ. Unravelling the differences between complexity and frailty in old age:     44. Ayus JC, Negri AL, Kalantar-Zadeh K, Moritz ML. Is chronic hyponatremia a novel
     findings from a constructivist grounded theory study. J Psychiatr Ment Health Nurs          risk factor for hip fracture in the elderly? Nephrol Dial Transplant 2012; 27:3725–31.
     2011; 18:67–73.                                                                         45. Musso CG, Jauregui JR, Macías Núñez JF. Frailty phenotype and chronic kidney dis­
 20. Landi F, Calvani R, Tosato M, et al. Anorexia of aging: risk factors, consequences,         ease: a review of the literature. Int Urol Nephrol 2015; 47:1801–7.
     and potential treatments. Nutrients 2016; 8:69.                                         46. McAdams-DeMarco MA, Law A, Salter ML, Boyarsky B, Gimenez L, Jaar BG, et al.
 21. Chapman IM. Endocrinology of anorexia of ageing. Best Pract Res Clin Endocrinol             Frailty as a novel predictor of mortality and hospitalization in individuals of all ages
     Metab 2004; 18:437–52.                                                                      undergoing hemodialysis. J Am Geriatr Soc 2013; 61:896–90.
 22. Marzetti E, Calvani R, Tosato M, Cesari M, Di Bari M, Cherubini A, et al. Sarcopenia:   47. Abbatecola AM, Paolisso G. Is there a relationship between insulin resistance and
     an overview. Aging Clin Exp Res 2017; 29:11–7.                                              frailty syndrome? Curr Pharm Des 2008; 14:405–10.
Expert consensus document on the management of arrhythmias in frailty syndrome                                                                                                        1273


48. Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I, et al. A                      76. Toff WD, Camm AJ, Skehan JD, United Kingdom P, Cardiovascular Events Trial I.
    global clinical measure of fitness and frailty in elderly people. CMAJ 2005; 173:                   Single-chamber versus dual-chamber pacing for high-grade atrioventricular block. N
    489–95.                                                                                             Engl J Med 2005; 353:145–55.
49. Buta BJ, Walston JD, Godino JG, Park M, Kalyani RR, Xue QL, et al. Frailty assess­              77. Kerr CR, Connolly SJ, Abdollah H, et al. Canadian Trial of Physiological Pacing: ef­
    ment instruments: Systematic characterization of the uses and contexts of highly-                   fects of physiological pacing during long-term follow-up. Circulation 2004; 109:
    cited instruments. Ageing Res Rev 2016; 26:53–61.                                                   357–62.
50. Dent E, Kowal P, Hoogendijk EO. Frailty measurement in research and clinical prac­              78. Lamas GA, Lee KL, Sweeney MO, et al. Ventricular pacing or dual-chamber pacing
    tice: a review. Eur J Intern Med 2016; 31:3–10.                                                     for sinus-node dysfunction. N Engl J Med 2002; 346:1854–62.
51. Veronese N, Cereda E, Stubbs B, Solmi M, Luchini C, Manzato E, et al. Risk of car­              79. Slotwiner D, Varma N, Akar JG, et al. HRS Expert Consensus Statement on remote




                                                                                                                                                                                                  Downloaded from https://academic.oup.com/europace/article/25/4/1249/7036349 by Uniwersytet Jagiellonsky w Krakowie user on 05 August 2024
    diovascular disease morbidity and mortality in frail and pre-frail older adults: results            interrogation and monitoring for cardiovascular implantable electronic devices.
    from a meta-analysis and exploratory meta-regression analysis. Ageing Res Rev                       Heart Rhythm 2015; 12:e69-100.
    2017; 35:63–73.                                                                                 80. Boveda S, Marijon E, Lenarczyk R, Iliodromitis KE, Marin F, Defaye P, et al. Factors
52. Stewart R. Cardiovascular disease and frailty: what are the mechanistic links? Clin                 influencing the use of leadless or transvenous pacemakers: results of the European
    Chem 2019; 65:80–6.                                                                                 Heart Rhythm Association Prospective Survey. Europace 2020; 22:667–73.
53. Fleg JL, Aronow WS, Frishman WH. Cardiovascular drug therapy in the elderly:                    81. Defaye P, Klug D, Anselme F, Gras D, Hermida JS, Piot O, et al. Recommendations
    benefits and challenges. Nat Rev Cardiol 2011; 8:13–28.                                             for the implantation of leadless pacemakers from the French Working Group on
54. Lee H-C, Huang K, Shen W-K. Use of antiarrhythmic drugs in elderly patients. J                      Cardiac Pacing and Electrophysiology of the French Society of Cardiology. Arch
    Geriatric Cardiology 2011; 8:184–94.                                                                Cardiovasc Dis 2018; 111:53–8.
55. Deneer VH, van Hemel NM. Is antiarrhythmic treatment in the elderly different? A                82. Higuchi S, Okada A, Shoda M, Yagishita D, Saito S, Kanai M, et al. Leadless cardiac
    review of the specific changes. Drugs Aging 2011; 28:617–33.                                        pacemaker implantations after infected pacemaker system removals in octogenar­
56. Dan GA, Martinez-Rubio A, Agewall S, Boriani G, Borggrefe M, Gaita F, et al.                        ians. J Geriatr Cardiol 2021; 18:505–13.
    Antiarrhythmic drugs-clinical use and clinical decision making: a consensus docu­               83. Curtis AB, Karki R, Hattoum A, Sharma UC. Arrhythmias in patients 80 years of
    ment from the European Heart Rhythm Association (EHRA) and European                                 age: pathophysiology, management, and outcomes. J Am Coll Cardiol 2018; 71:
    Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, en­                       2041–57.
    dorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society                     84. Raybaud F, Camous JP, Tibi T, Baudouy M, Morand P. [Severe arrhythmia in the eld­
    (APHRS) and International Society of Cardiovascular Pharmacotherapy (ISCP).                         erly: a prospective hospital study]. Arch Mal Coeur Vaiss 1995; 88:27–33.
    Europace 2018; 20:731–2.                                                                        85. Sherman H, Sandberg S, Fineberg HV. Exponential increase in age-specific preva­
57. Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev                        lence of ventricular dysrhythmia among males. J Chronic Dis 1982; 35:743–50.
    2009; 41:67–7.                                                                                  86. Arnar DO, Mairesse GH, Boriani G, Calkins H, Chin A, Coats A, et al. Management
58. Shi S, Klotz U. Age-related changes in pharmacokinetics. Curr Drug Metab 2011; 12:
                                                                                                        of asymptomatic arrhythmias: a European Heart Rhythm Association (EHRA) con­
    601–10.
                                                                                                        sensus document, endorsed by the Heart Failure Association (HFA), Heart Rhythm
59. Boriani G, Savelieva I, Dan GA, Deharo JC, Ferro C, Israel CW, et al. hronic kidney
                                                                                                        Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia
    disease in patients with cardiac rhythm disturbances or implantable electrical de­
                                                                                                        Society of Southern Africa (CASSA), and Latin America Heart Rhythm Society
    vices: clinical significance and implications for decision making-a position paper of
                                                                                                        (LAHRS). Europace 2019; 21:844–5.
    the European Heart Rhythm Association endorsed by the Heart Rhythm Society
                                                                                                    87. Rubart M, Zipes DP. Mechanisms of sudden cardiac death. J Clin Invest 2005; 115:
    and the Asia Pacific Heart Rhythm Society. Europace 2015; 17:1169–96.
                                                                                                        2305–15.
60. Zimetbaum P. Amiodarone for atrial fibrillation. N Engl J Med 2007; 356:935–41.
                                                                                                    88. Murphy DJ, Murray AM, Robinson BE, Campion EW. Outcomes of cardiopulmon­
61. El-Desoky ES. Pharmacokinetic-pharmacodynamic crisis in the elderly. Am J Ther
                                                                                                        ary resuscitation in the elderly. Ann Intern Med 1989; 111:199–205.
    2007; 14:488–98.
                                                                                                    89. Bayer AJ, Ang BC, Pathy MS. Cardiac arrests in a geriatric unit. Age and Ageing 1985;
62. American Geriatrics Society 2015 Updated Beers criteria for potentially inappro­
                                                                                                        14: 271–76.
    priate medication use in older adults. J Am Geriatr Soc 2015; 63:2227–46.
                                                                                                    90. Manolis AS, Deering TF, Cameron J, Estes NA 3rd. Mexiletine: pharmacology and
63. Moghtadaei M, Jansen HJ, Mackasey M, et al. The impacts of age and frailty on heart
                                                                                                        therapeutic use. Clin Cardiol 1990; 13:349–59.
    rate and sinoatrial node function. J Physiol 2016; 594:7105–26.
                                                                                                    91. Fitton A, Sorkin EM. Sotalol. An updated review of its pharmacological properties
64. Kumar P, Kusumoto FM, Goldschlager N. Bradyarrhythmias in the elderly. Clin
                                                                                                        and therapeutic use in cardiac arrhythmias. Drugs 1993; 46:678–719.
    Geriatr Med 2012; 28:703–15.
                                                                                                    92. Simantirakis EN, Koutalas EP, Vardas PE. Arrhythmia-induced cardiomyopathies:
65. Wakida Y, Okamoto Y, Iwa T, Yonemoto T, Kanemaki K, Shiomi T, et al.
                                                                                                        the riddle of the chicken and the egg still unanswered? Europace 2012; 14:466–73.
    Arrhythmias in centenarians. Pacing Clin Electrophysiol 1994; 17:2217–21.
                                                                                                    93. Park KM, Im SI, Chun KJ, Hwang JK, Park SJ, Kim JS, On YK. Asymptomatic ventricu­
66. Dungen HD, Apostolovic S, Inkrot S, et al. Titration to target dose of bisoprolol vs.
    carvedilol in elderly patients with heart failure: the CIBIS-ELD trial. Eur J Heart Fail            lar premature depolarizations are not necessarily benign. Europace 2016; 18:881–7.
                                                                                                    94. Marcus GM. Evaluation and management of premature ventricular complexes.
    2011; 13:670–80.
67. Zeltser D, Justo D, Halkin A, et al. Drug-induced atrioventricular block: prognosis                 Circulation 2020; 141:1404–18.
    after discontinuation of the culprit drug. J Am Coll Cardiol 2004; 44:105–8.                    95. Blandino A, Bianchi F, Frankel DS, Liang JJ, Mazzanti A, D’Ascenzo F, et al. Safety and
68. Gill SS, Anderson GM, Fischer HD, et al. Syncope and its consequences in patients                   efficacy of catheter ablation for ventricular tachycardia in elderly patients with
    with dementia receiving cholinesterase inhibitors: a population-based cohort study.                 structural heart disease: a systematic review and meta-analysis. J Interv Card
    Arch Intern Med 2009; 169:867–73.                                                                   Electrophysiol 2021. doi:10.1007/s10840-021-01007-w
69. Eriksson P, Hansson PO, Eriksson H, Dellborg M. Bundle-branch block in a general                96. Vakil K, Garcia S, Tung R, Vaseghi M, Tedrow U, Della Bella P, et al. Ventricular
    male population: the study of men born 1913. Circulation 1998; 98:2494–500.                         tachycardia ablation in the elderly: an International Ventricular Tachycardia
70. Fahy GJ, Pinski SL, Miller DP, et al. Natural history of isolated bundle branch block.              Center Collaborative Group Analysis. Circ Arrhythm Electrophysiol 2017; 10:
    Am J Cardiol 1996; 77:1185–90.                                                                      e005332.
71. Kreger BE, Anderson KM, Kannel WB. Prevalence of intraventricular block in the                  97. Priori SG, Blomström-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, et
    general population: the Framingham Study. Am Heart J 1989; 117:903–10.                              al. 2015 ESC Guidelines for the management of patients with ventricular arrhyth­
72. Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, et al.                    mias and the prevention of sudden cardiac death. Europace 2015; 17:1601–87.
    2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy.                    98. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or
    Europace 2022; 24:71–164.                                                                           an implantable cardioverter-defibrillator for congestive heart failure. New Engl J
73. Kusumoto FM, Schoenfeld MH, Barrett C, Edgerton JR, Ellenbogen KA, Gold MR, et                      Med 2005; 352:225–37.
    al. 2018 ACC/AHA/HRS Guideline on the evaluation and management of patients                     99. Zakine C, Garcia R, Narayan K, Gandjbakhch E, Algalarrondo V, Lellouche N, et al.
    with bradycardia and cardiac conduction delay: A report of the American College                     Prophylactic implantable cardioverter-defibrillator in the very elderly. Europace
    of Cardiology/American Heart Association Task Force on Clinical Practice                            2019; 21:1063–9.
    Guidelines and the Heart Rhythm Society. Circulation 2019; 140:e382-e482.                      100. Green AR, Leff B, Wang Y, Spartz ES, Masoudi FA, Peterson P, et al. Geriatric con­
74. Menozzi C, Brignole M, Alboni P, et al. The natural course of untreated sick sinus                  ditions in patients undergoing defibrillator implantation for prevention of sudden
    syndrome and identification of the variables predictive of unfavorable outcome. Am                  cardiac death: prevalence and impact on mortality. Circ Cardiovasc Qual Outcomes
    J Cardiol 1998; 82:1205–9.                                                                          2016; 9:23–30.
75. Link MS, Estes NA, 3rd, Griffin JJ, et al. Complications of dual chamber pacemaker im­         101. Poupin P, Bouleti C, Degand B, et al. Prognostic value of Charlson Comorbidity
    plantation in the elderly. Pacemaker Selection in the Elderly (PASE) Investigators. J Interv        Index in the elderly with a cardioverter-defibrillator implantation. Int J Cardiol
    Card Electrophysiol 1998; 2:175–9.                                                                  2020; 314:64–9.
1274                                                                                                                                                                     I. Savelieva et al.


102. Fauchier L, Marijon E, Defaye P, Piot O, Sadoul N, Perier MC, et al. Effect of age on      124. Bibas L, Levi M, Touchette J, Mardigyan V, Bernier M, Essebag V, Afilalo J.
     survival and causes of death after primary prevention implantable cardioverter-                 Implications of frailty in elderly patients with electrophysiological conditions.
     defibrillator implantation. Am J Cardiol 2015; 115:1415–22.                                     JACC Clin Electrophysiol 2016; 2:288–94.
103. Healey JS, Hallstrom AP, Kuck K-H, Nair G, Schron EP, Roberts RS, et al. Role of the       125. Dominguez-Rodriguez A, Abreu-Gonzalez P, Jimenez-Sosa A, Gonzalez J,
     implantable defibrillator among elderly patients with a history of life-threatening             Caballero-Estevez N, Martin-Casanas FV, et al. The impact of frailty in older pa­
     ventricular arrhythmias. Eur Heart J 2007; 28:1746–9.                                           tients with non-ischaemic cardiomyopathy after implantation of cardiac resynchro­
104. Goonewardene M, Barra S, Heck P, Begley D, Fynn S, Virdee M, et al. Cardioverter-               nization therapy defibrillator. Europace 2015; 17:598–602.
     defibrillator implantation and generator replacement in the octogenarian. Europace         126. Takeda T, Tsubaki A, Ikeda Y, Kato R, Hotta K, Inoue T, et al. The impacts of pre­
     2015; 17:409–46.                                                                                operative frailty on readmission after cardiac implantable electrical device implant­




                                                                                                                                                                                                  Downloaded from https://academic.oup.com/europace/article/25/4/1249/7036349 by Uniwersytet Jagiellonsky w Krakowie user on 05 August 2024
105. Barra S, Providência R, Paiva L, Heck P, Agarwal S. Implantable cardioverter-defi­              ation. PLoS One 2022; 17:e0277115.
     brillators in the elderly: rationale and specific age-related considerations.              127. Kramer DB, Tsai T, Natarajan P, Tewksbury E, Mitchell SL, Travison TG. Frailty,
     Europace 2015; 17:174–86.                                                                       physical activity, and mobility in patients with cardiac Implantable electrical devices.
106. Fauchier L, Alonso C, Anselme F, Blangy H, Bordachar P, Boveda S, et al. Position               J Am Heart Assoc 2017; 6:e004659.
     paper for management of elderly patients with pacemakers and implantable cardiac           128. Padeletti L, Arnar DO, Boncinelli L, Brachman J, Camm AJ, Daubert JC, et al. EHRA
                                                                                                     Expert Consensus Statement on the management of cardiovascular implantable
     defibrillators: Groupe de Rythmologie et Stimulation Cardiaque de la Societe
                                                                                                     electronic devices in patients nearing end of life or requesting withdrawal of ther­
     Francaise de Cardiologie and Societe Francaise de Geriatrie et Gerontologie.
                                                                                                     apy. Europace 2010; 12:1480–9.
     Arch Cardiovasc Dis 2016; 109:563–85.
                                                                                                129. Thylén I, Moser DK, Strömberg A. Octo- and nonagenarians’ outlook on life and
107. Chen MY, Orkaby AR, Rosenberg MA, Driver JA. Frailty, implantable cardioverter-
                                                                                                     death when living with an implantable cardioverter defibrillator: a cross-sectional
     defibrillators, and mortality: a systematic review. J Gen Intern Med 2019; 34:
                                                                                                     study. BMC Geriatr 2018; 18:250.
     2224–31.
                                                                                                130. Khurshid S, Choi SH, Weng LC, Wang EY, Trinquart L, Benjamin EJ, et al. Frequency
108. Bibas L, Levi M, Touchette J, Mardigyan V, Bernier M, Essebag V, Afilalo J.
                                                                                                     of cardiac rhythm abnormalities in a half million adults. Circ Arrhythm Electrophysiol
     Implications of frailty in elderly patients with electrophysiological conditions.
                                                                                                     2018; 11:e006273.
     JACC Clin Electrophysiol 2016; 2:288–94.                                                   131. Granada J, Uribe W, Chyou PH, Maassen K, Vierkant R, Smith PN, et al. Incidence
109. Wathen MS, DeGroot PJ, Sweeney MO, Stark AJ, Otterness MF, Adkisson WO,                         and predictors of atrial flutter in the general population. J Am Coll Cardiol 2000; 36:
     et al. Prospective randomized multicenter trial of empirical antitachycardia pacing             2242–6.
     versus shocks for spontaneous rapid ventricular tachycardia in patients with im­           132. Brembilla-Perrot B, Sellal JM, Olivier A, Manenti V, Villemin T, Beurrier D, et al. Risk
     plantable cardioverter-defibrillators: Pacing Fast Ventricular Tachycardia Reduces              and outcome after ablation of isthmus-dependent atrial flutter in elderly patients.
     Shock Therapies (PainFREE Rx II) trial results. Circulation 2004; 110:2591–6.                   PLoS One 2015; 10:e0127672.
110. Wilkoff BL, Williamson BD, Stern RS, Moore SL, Lu F, Lee SW, et al. Strategic pro­         133. Epstein LM, Chiesa N, Wong MN, Lee RJ, Griffin JC, Scheinman MM, Lesh MD.
     gramming of detection and therapy parameters in implantable cardioverter-defi­                  Radiofrequency catheter ablation in the treatment of supraventricular tachycardia
     brillators reduces shocks in primary prevention patients: results from the                      in the elderly. J Am Coll Cardiol 1994; 23:1356–62.
     PREPARE (Primary Prevention Parameters Evaluation) study. J Am Coll Cardiol                134. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al.
     2008; 52:541–50.                                                                                2020 ESC Guidelines for the diagnosis and management of atrial fibrillation devel­
111. Moss AJ, Schuger C, Beck CA, Brown MW, Cannom DS, Daubert JP, et al.                            oped in collaboration with the European Association for Cardio-Thoracic Surgery
     Reduction in inappropriate therapy and mortality through ICD programming.                       (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of
     New Engl J Med 2012; 367:2275–83.                                                               the European Society of Cardiology (ESC) Developed with the special contribution
112. Wilkoff BL, Fauchier L, Stiles MK, Morillo CA, Al-Khatib SM, Almendral J, et al. 2015           of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021;
     HRS/EHRA/APHRS/SOLAECE Expert consensus statement on optimal implanta­                          42:373–498.
     ble cardioverter-defibrillator programming and testing. Europace 2016; 18:159–83.          135. Polidoro A, Stefanelli F, Ciacciarelli M, Pacelli A, Di Sanzo D, Alessandri C. Frailty in
113. Stiles MK, Fauchier L, Morillo CA, Wilkoff BL. 2019 HRS/EHRA/APHRS/LAHRS fo­                    patients affected by atrial fibrillation. Arch Gerontol Geriatr 2013; 57:325–7.
     cused update to 2015 expert consensus statement on optimal implantable cardio­             136. Wilkinson C, Todd O, Clegg A, Gale CP, Hall M. Management of atrial fibrillation
     verter-defibrillator programming and testing. Europace 2019; 21:1442–3.                         for older people with frailty: a systematic review and meta-analysis. Age Ageing
114. McLeod CJ, Boersma L, Okamura H, Friedman PA. The subcutaneous implantable                      2019; 48:196–203.
     cardioverter defibrillator: state-of-the-art review. Eur Heart J 2017; 38:247–57.          137. Villani ER, Tummolo AM, Palmer P, Gravina EM, Vetrano DL, Bernabei R, et al.
115. Joseph SM, Rich MW. Targeting frailty in heart failure. Curr Treat Options Cardiovasc           Frailty and atrial fibrillation: A systematic review. Eur J Intern Med 2018; 56:33–8.
     Med 2017; 19:31.                                                                           138. Ekerstad N, Karlsson T, Soderqvist S, Karlson BW. Hospitalized frail elderly patients -
116. Walston J, Hadley EC, Ferrucci L, et al. Research agenda for frailty in older adults:           atrial fibrillation, anticoagulation and 12 months’ outcomes. Clin Interv Aging 2018; 3:
     toward a better understanding of physiology and etiology: summary from the                      749–56.
     American Geriatrics Society/National Institute on Aging Research Conference                139. Lip GYH. The ABC pathway: an integrated approach to improve AF management.
     on Frailty in Older Adults. J Am Geriatr Soc 2006; 54:991–1001.                                 Nat Rev Cardiol 2017; 14: 627–8.
117. McDonagh J, Martin L, Ferguson C, et al. Frailty assessment instruments in heart           140. Kotecha D, Bunting KV, Gill SK, Mehta S, Stanbury M, Jones JC, et al. Effect of di­
                                                                                                     goxin vs bisoprolol for heart rate control in atrial fibrillation on patient-reported
     failure: a systematic review. Eur J Cardiovasc Nurs 2018; 17:23–35.
                                                                                                     quality of life: the RATE-AF randomized clinical trial. JAMA 2020; 324:2497–508.
118. Seferovic PM, Ponikowski P, Anker SD, Bauersachs J, Chioncel O, Cleland JGF, et al.
                                                                                                141. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD,
     Clinical practice update on heart failure 2019: pharmacotherapy, procedures, de­
                                                                                                     et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin
     vices and patient management. An expert consensus meeting report of the
                                                                                                     in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;
     Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail
                                                                                                     383:955–62.
     2019; 21:1169–86.
                                                                                                142. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC
119. Kubala M, Guédon-Moreau L, Anselme F, Klug D, Bertaina G, Traullé S, et al. Utility
                                                                                                     Guidelines for the management of atrial fibrillation developed in collaboration
     of frailty assessment for elderly patients undergoing cardiac resynchronization
                                                                                                     with EACTS. Europace 2016; 18:1609–78.
     therapy. JACC Clin Electrophysiol 2017; 3:1523–33.                                         143. Esteve-Pastor MA, Rivera-Caravaca JM, Shantsila A, Roldán V, Lip GYH, Marín F.
120. Fumagalli S, Pieragnoli P, Ricciardi G, Mascia G, Mascia F, Michelotti F, et al. Cardiac        Assessing bleeding risk in atrial fibrillation patients: comparing a bleeding risk score
     resynchronization therapy improves functional status and cognition. Int J Cardiol               based only on modifiable bleeding risk factors against the HAS-BLED Score. The
     2016; 219:212–7.                                                                                AMADEUS Trial. Throm Haemost 2017; 117: 2261–6.
121. Milner A, Braunstein ED, Umadat G, Ahsan H, Lin J, Palma E. Utility of the modified        144. Chao TF, Lip GYH, Lin YJ, Chang SL, Lo LW, Hu YF, et al. Major bleeding and intra­
     frailty index to predict cardiac resynchronization therapy outcomes and response.               cranial hemorrhage risk prediction in patients with atrial fibrillation: Attention to
     Am J Cardiol 2020; 125:1077–82.                                                                 modifiable bleeding risk factors or use of a bleeding risk stratification score? A na­
122. Sergi G, Veronese N, Fontana L, De Rui M, Bolzetta F, Zambon S, et al. Pre-frailty              tionwide cohort study. Int J Cardiol 2018; 254:157–61.
     and risk of cardiovascular disease in elderly men and women: the Pro.V.A. study. J Am      145. Guo Y, Zhu H, Chen Y, Lip GYH. Comparing bleeding risk assessment focused on
     Coll Cardiol 2015; 65:976–83.                                                                   modifiable risk factors only versus validated bleeding risk scores in atrial fibrillation.
123. Setoguchi S, Warner Stevenson L, Stewart GC, Bhatt DL, Epstein AE, et al.                       Am J Med 2018; 131:185–92.
     Influence of healthy candidate bias in assessing clinical effectiveness for implantable    146. Lefebvre MC, St-Onge M, Glazer-Cavanagh M, et al. The effect of bleeding risk and
     cardioverter-defibrillators: cohort study of older patients with heart failure. BMJ             frailty status on anticoagulation patterns in octogenarians with atrial fibrillation: the
     May 8 2014; 348:g2866.                                                                          FRAIL-AF study. Can J Cardiol 2016; 32:169–76.
Expert consensus document on the management of arrhythmias in frailty syndrome                                                                                                          1275


147. Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in       169. Bunch TJ, Weiss JP, Crandall BG, May HT, Bair TL, Osborn JS, et al. Long-term clin­
     an elderly community population with atrial fibrillation (the Birmingham Atrial                  ical efficacy and risk of catheter ablation for atrial fibrillation in octogenarians. Pacing
     Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial.                 Clin Electrophysiol 2010; 33:146–52.
     Lancet 2007; 370:493–503.                                                                   170. Santangeli P, Di Biase L, Mohanty P, Burkhardt JD, Horton R, Bai R, et al. Catheter
148. Chao TF, Liu CJ, Lin YJ, Chang SL, Lo LW, Hu YF, et al. Oral anticoagulation in very             ablation of atrial fibrillation in octogenarians: safety and outcomes. J Cardiovasc
     elderly patients with atrial fibrillation: a nationwide cohort study. Circulation 2018;          Electrophysiol 2012; 23:687–93.
     138:37–47.                                                                                  171. Natale V, Mohanty S, Trivedi C, Baqai FM, Gallinghouse J, Della Rocca DG, et al.
149. Lauw MN, Eikelboom JW, Coppens M, Wallentin L, Yusuf S, Ezekowitz M, et al.                      Arrhythmia profile and ablation-outcome in elderly women with atrial fibrillation
     Effects of dabigatran according to age in atrial fibrillation. Heart 2017; 103:1015–23.          undergoing first catheter ablation. Pacing Clin Electrophysiol 2021; 44:835–42.




                                                                                                                                                                                                     Downloaded from https://academic.oup.com/europace/article/25/4/1249/7036349 by Uniwersytet Jagiellonsky w Krakowie user on 05 August 2024
150. Halperin JL, Hankey GJ, Wojdyla DM, Piccini JP, Lokhnygina Y, Patel MR, et al.              172. Kundi H, Noseworthy PA, Valsdottir LR, Shen C, Yao X, Yeh RW, Kramer DB.
     Efficacy and safety of rivaroxaban compared with warfarin among elderly patients                 Relation of frailty to outcomes after catheter ablation of atrial fibrillation. Am J
     with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct                 Cardiol 2020; 125:1317–23.
     Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of                   173. Yang PS, Sung JH, Kim D, Jang E, Yu HT, Kim TH, et al. Frailty and the effect of cath­
     Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation 2014;                  eter ablation in the elderly population with atrial fibrillation - a real-world analysis.
     130:138–46.                                                                                      Circ J 2021; 85:1305–13.
151. Halvorsen S, Atar D, Yang H, De Caterina R, Erol C, Garcia D, et al. Efficacy and           174. Packer DL, Mark DB, Robb RA, Monahan KH, Bahnson TD, Poole JE, et al. Effect of
     safety of apixaban compared with warfarin according to age for stroke prevention                 catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and
     in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J 2014; 35:             cardiac arrest among patients with atrial fibrillation: the CABANA randomized clin­
     864–72.                                                                                          ical trial. JAMA 2019; 321:1261–74.
152. Kato ET, Giugliano RP, Ruff CT, Koretsune Y, Yamashita T, Kiss RG, et al. Efficacy          175. Boriani G, Laroche C, Diemberger I, Fantecchi E, Popescu MI, Rasmussen LH, et al.
     and safety of edoxaban in elderly patients with atrial fibrillation in the ENGAGE AF-            Asymptomatic atrial fibrillation: clinical correlates, management, and outcomes in
     TIMI 48 trial. J Am Heart Assoc 2016; 5:e003432.                                                 the EORP-AF Pilot General Registry. Am J Med 2015; 128:509–18.e2.
153. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, et al. Apixaban in       176. Siontis KC, Gersh BJ, Killian JM, Noseworthy PA, McCabe P, Weston SA, et al.
     patients with atrial fibrillation. New Engl J Med 2011; 364:806–17.                              Typical, atypical, and asymptomatic presentations of new-onset atrial fibrillation
154. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent                 in the community: Characteristics and prognostic implications. Heart Rhythm
     stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146:           2016; 13:1418–24.
                                                                                                 177. Mairesse GH, Moran P, Van Gelder IC, Elsner C, Rosenqvist M, Mant J, et al.
     857–67.
155. Dagres N, Chao TF, Fenelon G, et al. European Heart Rhythm Association (EHRA)/                   Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) con­
                                                                                                      sensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart
     Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin
                                                                                                      Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardíaca
     American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and
                                                                                                      y Electrofisiología (SOLAECE). Europace 2017; 19:1589–1623.
     cognitive function: what is the best practice? Europace 2018; 20:1399–421.
                                                                                                 178. Zink MD, Mischke KG, Keszei AP, Rummey C, Freedman B, Neumann G, et al.
156. Mongkhon P, Naser AY, Fanning L, Tse G, Lau WCY, Wong ICK, Kongkaew C.
                                                                                                      Screen-detected atrial fibrillation predicts mortality in elderly subjects. Europace
     Oral anticoagulants and risk of dementia: a systematic review and meta-analysis
                                                                                                      2021; 23:29–38.
     of observational studies and randomized controlled trials. Neurosci Biobehav Rev
                                                                                                 179. Lopez Perales CR, Van Spall HGC, Maeda S, Jimenez A, Laţcu DG, Milman A, et al.
     2018; 96:1–9.
                                                                                                      Mobile health applications for the detection of atrial fibrillation: a systematic review.
157. Rao MP, Vinereanu D, Wojdyla DM, Alexander JH, Atar D, Hylek EM. Clinical out­
                                                                                                      Europace 2021; 23:11–28.
     comes and history of fall in patients with atrial fibrillation treated with oral anticoa­
                                                                                                 180. Freedman B, Camm J, Calkins H, Healey JS, Rosenqvist M, Wang J, et al. Screening
     gulation: insights from the ARISTOTLE Trial. Am J Med 2018; 131:269–75.
                                                                                                      for Atrial Fibrillation: A Report of the AF-SCREEN International Collaboration.
158. Steffel J, Giugliano RP, Braunwald E, Murphy SA, Mercuri M, Choi Y, et al. Edoxaban
                                                                                                      Circulation 2017; 135:1851–67.
     versus warfarin in atrial fibrillation patients at risk of falling: ENGAGE AF-TIMI 48
                                                                                                 181. Gorenek B, Bax J, Boriani G, Chen SA, Dagres N, Glotzer TV, et al. Device-detected
     Analysis. J Am Col Cardiol 2016; 68:1169–78.
                                                                                                      subclinical atrial tachyarrhythmias: definition, implications and management-an
159. Kim DH, Pawar A, Gagne JJ, Bessette LG, Lee H, Glynn RJ, et al. Frailty and clinical
                                                                                                      European Heart Rhythm Association (EHRA) consensus document, endorsed by
     outcomes of direct oral anticoagulants versus warfarin in older adults with atrial
                                                                                                      Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS) and
     fibrillation: a cohort study. Ann Intern Med 2021; 174:1214–23.
                                                                                                      Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología
160. Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, et al. 2021 European
                                                                                                      (SOLEACE). Europace 2017; 19:1556–78.
     Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K
                                                                                                 182. Boriani G, Glotzer TV, Santini M, West TM, De Melis M, Sepsi M, et al. Device-de­
     Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace 2021;
                                                                                                      tected atrial fibrillation and risk for stroke: an analysis of >10,000 patients from the
     23:1612–76.                                                                                      SOS AF project (Stroke preventiOn Strategies based on Atrial Fibrillation informa­
161. van Doorn S, Tavenier A, Rutten FH, Hoes AW, Moons KGM, Geersing GJ. Risk of
                                                                                                      tion from implanted devices). Eur Heart J 2014; 35:508–16.
     cardiac and non-cardiac adverse events in community-dwelling older patients with            183. Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A, et al.
     atrial fibrillation: a prospective cohort study in the Netherlands. BMJ Open 2018; 8:            Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 2012; 366:120–9.
     e021681.                                                                                    184. Freedman B, Boriani G, Glotzer TV, Healey JS, Kirchhof P, Potpara TS. Management
162. Martinez BK, Sood NA, Bunz TJ, Coleman CI. Effectiveness and safety of apixaban,                 of atrial high-rate episodes detected by cardiac implanted electronic devices. Nat
     dabigatran, and rivaroxaban versus warfarin in frail patients with nonvalvular atrial            Rev Cardiol 2017; 14:701–14.
     fibrillation. J Am Heart Assoc 2018; 7:e008643.                                             185. Mahajan R, Perera T, Elliott AD, Twomey DJ, Kumar S, Munwar DA, et al.
163. Okumura K, Akao M, Yoshida T, Kawata M, Okazaki O, Akashi S, et al. Low-dose                     Subclinical device-detected atrial fibrillation and stroke risk: a systematic review
     edoxaban in very elderly patients with atrial fibrillation. N Engl J Med 2020; 383:              and meta-analysis. Eur Heart J 2018; 39:1407–15.
     1735–45.                                                                                    186. Svendsen JH, Diederichsen SZ, Højberg S, Krieger DW, Graff C, Kronborg C, et al.
164. Wang A, Ferro EG, Song Y, Xu J, Sun T, Yeh RW, Strom JB, Kramer DB. Frailty in                   Implantable loop recorder detection of atrial fibrillation to prevent stroke (The
     patients undergoing percutaneous left atrial appendage closure. Heart Rhythm                     LOOP Study): a randomised controlled trial. Lancet 2021; 398:1507–16.
     2022:S1547–5271(22)00012-1.                                                                 187. Boriani G, Glotzer TV, Ziegler PD, De Melis M, Mangoni, di S Stefano L, et al.
165. Nguyen TN, Cumming RG and Hilmer SN. Atrial fibrillation in older inpatients: are                Detection of new atrial fibrillation in patients with cardiac implanted electronic devices
     there any differences in clinical characteristics and pharmacological treatment be­              and factors associated with transition to higher device-detected atrial fibrillation burden.
     tween the frail and the non-frail? Intern Med J 2016; 46:86–95.                                  Heart Rhythm 2018; 15:376–83.
166. Bibas L, Levi M, Touchette J, Mardigyan V, Bernier M, Essebag V, Afilalo J.                 188. Camm AJ, Simantirakis E, Goette A, Lip GY, Vardas P, Calvert M, et al. Atrial high-
     Implications of frailty in elderly patients with electrophysiological conditions.                rate episodes and stroke prevention. Europace. 2017; 19:169–79.
     JACC Clin Electrophysiol 2016; 2:288–94.                                                    189. Hess PL, Kim S, Piccini JP, et al. Use of evidence-based cardiac prevention therapy
167. Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L, et al. 2017                      among outpatients with atrial fibrillation. Am J Med. 2013; 126:625–632.e621.
     HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter                          190. Winovich DT, Longstreth WT, Jr., Arnold AM, et al. Factors associated with ische­
     and surgical ablation of atrial fibrillation. Europace 2018; 20:e1–160.                          mic stroke survival and recovery in older adults. Stroke. 2017; 48:1818–26.
168. Bunch TJ, May HT, Bair TL, Jacobs V, Crandall BG, Cutler M, et al. The Impact of Age        191. Dhamoon MS, Longstreth WT, Jr., Bartz TM, Kaplan RC, Elkind MSV. Disability tra­
     on 5-Year Outcomes After Atrial Fibrillation Catheter Ablation. J Cardiovasc                     jectories before and after stroke and myocardial infarction: the Cardiovascular
     Electrophysiol 2016; 27:141–6.                                                                   Health Study. JAMA Neurol 2017; 74:1439–45.
1276                                                                                                                                                                   I. Savelieva et al.


192. Biffi A, Kuramatsu JB, Leasure A, et al. Oral anticoagulation and functional outcome       211. De Lepeleire J, Iliffe S, Mann E, Degryse JM. Frailty: an emerging concept for general
     after intracerebral hemorrhage. Ann Neurol 2017; 82:755–65.                                     practice. Br J Gen Pract 2009; 59:e177–82.
193. Wilson D, Ambler G, Shakeshaft C, et al. Cerebral microbleeds and intracranial             212. Puts MT, Shekary N, Widdershoven G, Heldens J, Lips P, Deeg DJ. What does qual­
     haemorrhage risk in patients anticoagulated for atrial fibrillation after acute ischae­         ity of life mean to older frail and non-frail community-dwelling adults in the
     mic stroke or transient ischaemic attack (CROMIS-2): a multicentre observational                Netherlands? Qual Life Res 2007; 16:263–77.
     cohort study. Lancet Neurol 2018; 17:539–47.                                               213. Frewen J, Finucane C, Cronin H, et al. Factors that influence awareness and treat­
194. Whiteley WN, Adams HP, Jr., Bath PM, et al. Targeted use of heparin, heparinoids,               ment of atrial fibrillation in older adults. QJM 2013; 106:415–24.
     or low-molecular-weight heparin to improve outcome after acute ischaemic                   214. O’Brien EC, Holmes DN, Ansell JE, et al. Physician practices regarding contraindi­
     stroke: an individual patient data meta-analysis of randomised controlled trials.               cations to oral anticoagulation in atrial fibrillation: findings from the Outcomes




                                                                                                                                                                                               Downloaded from https://academic.oup.com/europace/article/25/4/1249/7036349 by Uniwersytet Jagiellonsky w Krakowie user on 05 August 2024
     Lancet Neurol 2013; 12:539–45.                                                                  Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry.
195. Hong KS, Kwon SU, Lee SH, et al. Rivaroxaban vs warfarin sodium in the ultra-early              Am J Cardiol 2014; 167:601–609.e601.
     period after atrial fibrillation-related mild ischemic stroke: a randomized clinical       215. Perera V, Bajorek BV, Matthews S, Hilmer SN. The impact of frailty on the utilisa­
     trial. JAMA Neurol 2017; 74:1206–15.                                                            tion of antithrombotic therapy in older patients with atrial fibrillation. Age Ageing
196. Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in             2009; 38:156–62.
     patients with stroke and transient ischemic attack: a guideline for healthcare pro­        216. Steinberg BA, Holmes DN, Ezekowitz MD, et al. Rate versus rhythm control for
     fessionals from the American Heart Association/American Stroke Association.                     management of atrial fibrillation in clinical practice: results from the Outcomes
     Stroke 2014; 45:2160–236.                                                                       Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry.
197. McGrath ER, Kapral MK, Fang J, et al. Which risk factors are more associated with               Am Heart J 2013; 165:622–9.
     ischemic stroke than intracerebral hemorrhage in patients with atrial fibrillation?        217. Goldfarb M, Sheppard R, Afilalo J. Prognostic and therapeutic implications of frailty
     Stroke 2012; 43:2048–54.                                                                        in older adults with heart failure. Curr Cardiol Rep 2015; 17:92.
198. Ng KH, Shestakovska O, Connolly SJ, et al. Efficacy and safety of apixaban com­            218. Shamliyan T, Talley KM, Ramakrishnan R, Kane RL. Association of frailty with sur­
     pared with aspirin in the elderly: a subgroup analysis from the AVERROES trial.                 vival: a systematic literature review. Ageing Res Rev 2013; 12:719–36.
                                                                                                219. Adelstein EC, Liu J, Jain S, Schwartzman D, Althouse AD, Wang NC, et al. Clinical
     Age Ageing. 2016; 45:77–83.
                                                                                                     outcomes in cardiac resynchronization therapy-defibrillator recipients 80 years of
199. Man-Son-Hing M, Nichol G, Lau A, Laupacis A. Choosing antithrombotic therapy
                                                                                                     age and older. Europace 2016; 18:420–7.
     for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med
                                                                                                220. Brenner R, Ammann P, Yoon SI, et al. Reduction of falls and fractures after perman­
     1999; 159:677–85.
                                                                                                     ent pacemaker implantation in elderly patients with sinus node dysfunction.
200. Diener HC, Weber R, Lip GY, Hohnloser SH. Stroke prevention in atrial fibrillation:
                                                                                                     Europace 2017; 19:1220–6.
     do we still need warfarin? Curr Opin Neurol 2012; 25:27–35.
                                                                                                221. Fletcher AE, Price GM, Ng ES, et al. Population-based multidimensional assessment
201. Parry SW, Steen IN, Baptist M, Kenny RA. Amnesia for loss of consciousness in ca­
                                                                                                     of older people in UK general practice: a cluster-randomised factorial trial. Lancet
     rotid sinus syndrome: implications for presentation with falls. J Am Coll Cardiol 2005;
                                                                                                     2004; 364:1667–77.
     45:1840–3.
                                                                                                222. Iliffe S, Gould M, Wallace P. Assessment of older people in the community: lessons
202. Kerr SR, Pearce MS, Brayne C, Davis RJ, Kenny RA. Carotid sinus hypersensitivity in
                                                                                                     from Britain’s ‘75-and-over checks’. Rev Clin Geront 1999; 9:305–16.
     asymptomatic older persons: implications for diagnosis of syncope and falls. Arch
                                                                                                223. Lane DA, Aguinaga L, Blomström-Lundqvist C, Boriani G, Dan GA, Hills MT, et al.
     Intern Med 2006; 166:515–20.
                                                                                                     Cardiac tachyarrhythmias and patient values and preferences for their manage­
203. Krediet CT, Parry SW, Jardine DL, Benditt DG, Brignole M, Wieling W. The history
                                                                                                     ment: the European Heart Rhythm Association (EHRA) consensus document en­
     of diagnosing carotid sinus hypersensitivity: why are the current criteria too sensi­
                                                                                                     dorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society
     tive? Europace 2010; 13:14–22.
                                                                                                     (APHRS), and Sociedad Latinoamericana de Estimulación Cardíaca y
204. Ungar A, Mussi C, Del Rosso A, Noro G, Abete P, Ghirelli L, et al. Diagnosis and
                                                                                                     Electrofisiología (SOLEACE). Europace 2015; 17:1747–69.
     characteristics of syncope in older patients referred to geriatric departments. J          224. Torres Roldan VD, Brand-McCarthy SR, Ponce OJ, Belluzzo T, Urtecho M,
     Am Geriatr Soc 2006; 54:1531–36.                                                                Espinoza Suarez NR, et al. Shared decision making tools for people facing stroke
205. Galizia G, Abete P, Mussi C, Noro G, Morrione A, Langellotto A, et al. Role of early            prevention strategies in atrial fibrillation: a systematic review and environmental
     symptoms in assessment of syncope in elderly people: results from the Italian group             scan. Med Decis Making 2021; 41:540–9.
     for the study of syncope in the elderly. J Am Geriatric Soc 2009:57:18–23.                 225. Kunneman M, Branda ME, Hargraves IG, Sivly AL, Lee AT, Gorr H, et al. Assessment
206. Del Rosso A, Bartoletti A, Bartoli P, Ungar A, Bonechi F, Maioli M, et al.                      of shared decision-making for stroke prevention in patients with atrial fibrillation: a
     Methodology of head-up tilt testing with sublingual nitroglycerin in unexplained                randomized clinical trial. JAMA Intern Med 2020; 180:1215–24.
     syncope. Am J Cardiol 2000; 85:1007–11.                                                    226. Pluymaekers NAHA, Hermans ANL, van der Velden RMJ, Gawałko M, den Uijl
207. Ungar A, Rivasi G, Rafanelli M, Toffanello G, Mussi C, Ceccofiglio A, et al. Safety and         DW, Buskes S, et al. Implementation of an on-demand app-based heart rate and
     tolerability of tilt testing and carotid sinus massage in the octogenarians. Age Ageing         rhythm monitoring infrastructure for the management of atrial fibrillation through
     2016; 45:242–48.                                                                                teleconsultation: TeleCheck-AF. Europace 2021; 23:345–52.
208. Solari D, Tesi F, Unterhuber M, Gaggioli G, Ungar A, Tomaino M, et al. Stop vaso­          227. Hermans ANL, van der Velden RMJ, Gawalko M, Verhaert DVM, Desteghe L,
     depressor drugs in reflex syncope: a randomised controlled trial. Heart 2017; 103:              Duncker D, et al. On-demand mobile health infrastructures to allow comprehen­
     449–55.                                                                                         sive remote atrial fibrillation and risk factor management through teleconsultation.
209. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018              Clin Cardiol 2020; 43:1232–9.
     ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018;          228. Lane DA, McMahon N, Gibson J, Weldon JC, Farkowski MM, Lenarczyk R, et al.
     39:3021–104.                                                                                    Mobile health applications for managing atrial fibrillation for healthcare profes­
210. Fanciulli A, Jordan J, Biaggioni I, Calandra–Buonaura G, Cheshire WP, Cortelli P, et            sionals and patients: a systematic review. Europace 2020; 22:1567–78.
     al. Consensus statement on the definition of neurogenic supine hypertension in             229. Leclercq C, Witt H, Hindricks G, Katra RP, Albert D, Belliger A, et al. Wearables,
     cardiovascular autonomic failure by the American Autonomic Society (AAS) and                    telemedicine, and artificial intelligence in arrhythmias and heart failure: Proceedings
     the European Federation of Autonomic Societies (EFAS). Clin Auton Res 2018;                     of the European Society of Cardiology Cardiovascular Round Table. Europace 2022;
     28:355–62.                                                                                      24:1372–83.
